NCT Number,Study Title,Study URL,Study Results,Conditions,Interventions,Sex,Age,Phases,Locations
NCT05928962,An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas,https://clinicaltrials.gov/study/NCT05928962,NO,Malignant Melanomas,DRUG: Recombinant Human Adenovirus Type 5 Injection,ALL,"ADULT, OLDER_ADULT",PHASE1,"Fujian Cancer Hospital, Department of Internal Medicine, Ward 19, Fuzhou, Fujian, China"
NCT01502696,Adjuvant PEG Intron in Ulcerated Melanoma,https://clinicaltrials.gov/study/NCT01502696,NO,Ulcerated Melanomas,BIOLOGICAL: PEG IFN alfa-2b,ALL,"ADULT, OLDER_ADULT",PHASE3,"Medical University of Graz, Graz, Austria|Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium|Aarhus University Hospital, Aarhus, 8000, Denmark|Herlev Hospital - University Copenhagen, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Assistance Publique - Hopitaux de Paris - Hopital Avicenne, Bobigny, France|CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre (Bordeaux, France, Bordeaux, France|CHU de Grenoble - La Tronche - Hôpital A. Michallon, Grenoble, France|CHRU de Lille, Lille, France|Centre Leon Berard, Lyon, France|Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone, Marseille, France|CHU de Nice - CHU de Nice - Hopital De L'Archet, Nice, France|Assistance Publique - Hopitaux de Paris - CHU Ambroise Pare, Paris, France|Assitance Publique - Hopitaux de Paris - Hopital Bichat-Claude Bernard, Paris, France|Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis, Paris, France|Institut Gustave Roussy, Paris, France|Centre Hospitalier De Pau, Pau, France|CHU de Reims - Hôpital Robert Debré, Reims, France|CHU d'Amiens - CHU Amiens - Hopital Sud, Salouel, France|Universitaetsklinikum, Essen, Germany|Universitaetsklinikum Heidelberg - Hautklinik / Dermatologic Department, Heidelberg, Germany|Universitaetsklinikum Heidelberg - Hautklinik, Heidelburg, Germany|Universitaetsklinikum Schleswig-Holstein, Kiel, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Medizinische Universitaet Zu Luebeck, Luebeck, Germany|Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center, Mainz, Germany|UniversitaetsMedizin Mannheim, Mannheim, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|IRCCS - Istituto Tumori ""Giovanni Paolo II"", Bari, Italy|Istituto Europeo di Oncologia, Milan, Italy|Istituto Nazionale Tumori IRCCS ""Fondazione G. Pascale"", Napoli, Italy|Istituto Dermopatico Dell'Immacolata, Roma, Italy|Azienda Ospedaliero-Universitaria ""Santa Maria della Misericordia"" di Udine, Udine, Italy|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland|I.P.O. Francisco Gentil - Centro De Lisboa, Lisboa, 1099-023, Portugal|I.P.O. Francisco Gentil - Centro De Lisboa, Lisboa, Portugal|Hospital Distrital De Santarem, Santarem, Portugal|Hospital Clinic Universitari, Barcelona, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|UniversitaetsSpital Zurich, Zurich, Switzerland|Clatterbridge Centre for Oncology NHS Trust - Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom|University Hospitals Birmingham NHS Foundation Trust (UHB) - Queen Elisabeth Medical Centre, Birmingham, United Kingdom|Mid Essex Hospitals - Broomfield Hospital, Broomfield, United Kingdom|Cambridge University Hospital NHS - Addenbrookes Hospital, Cambridge, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust - St. James's University Hospital, Leeds, United Kingdom|St George's Hospital NHS Trust (6961), London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Norfolk And Norwich Hospital, Norwich, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|University Hospital Southampton NHS Foundation Trust - Southampton General Hospital, Southampton, United Kingdom|St Helens and Knowsley Teaching Hospitals, St Helens, United Kingdom"
NCT03783325,Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma,https://clinicaltrials.gov/study/NCT03783325,NO,Nevi and Melanomas,BEHAVIORAL: UV Counseling|OTHER: UV Photo|OTHER: Biological Sample,ALL,"ADULT, OLDER_ADULT",NA,"University of Colorado, Aurora, Colorado, 80045, United States"
NCT04020809,Neoadjuvant Atezolizumab in Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT04020809,NO,Cutaneous Melanoma,DRUG: Atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"Houston Methodist Hospital, Houston, Texas, 77030, United States"
NCT03541148,Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT03541148,NO,"Cutaneous Melanoma, Stage II|Malignant Cutaneous Melanoma|Cutaneous Melanoma, Stage III",DIETARY_SUPPLEMENT: Oncoxin-Viusid,ALL,"ADULT, OLDER_ADULT",PHASE2,"Manuel Fajardo Clinical Surgical University Hospital, La Habana, 10600, Cuba"
NCT04702854,Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT04702854,NO,Cutaneous Melanoma,DIAGNOSTIC_TEST: Ultrasound Biomicroscopy,ALL,"ADULT, OLDER_ADULT",NA,"CHU de Nice, Nice, France"
NCT05172232,Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions,https://clinicaltrials.gov/study/NCT05172232,NO,Malignant Melanoma,DIAGNOSTIC_TEST: Dermalyzer,ALL,"ADULT, OLDER_ADULT",,"Region Östergötland Primary Care, Linköping, Docent, 58185, Sweden|Region Stockholm Primary Care, Stockholm, Sweden|Region Kalmar and Kronoberg, Växjö, Sweden"
NCT05572463,A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT05572463,NO,Unresectable Cutaneous Melanoma|Metastatic Cutaneous Melanoma,COMBINATION_PRODUCT: Sintilimab + IBI110,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"University of California San Francisco Medical Center, San Francisco, California, 94143, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Princess Victoria Hospital, Woolloongabba, Queensland, 4102, Australia|Hospices Civil De Lyon Nord - Centre Hospitalier Lyon Sud - Dermatologie, Lyon, 69002, France|Hospital Saint Louis, Paris, 75010, France|Universitatsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Universitatsklinikum Essen, Essen, 45147, Germany|Institut Catala d'Oncologia Hospital Universitari Germans Trials I Pujol, Barcelona, Barcelona, 8916, Spain|Hospital Universitario Reina Sofia, Cordoba, Córdoba, 14004, Spain|Universitaets Spital Zurich, Zürich, 8091, Switzerland|Cambridge University Hospitals NHS Foundation Trust (Oxford), Cambridge, CB2 0QQ, United Kingdom|Lancashire Teaching Hospitals (Preston), Preston, PR2 9HT, United Kingdom"
NCT04253080,Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors,https://clinicaltrials.gov/study/NCT04253080,NO,Cutaneous Melanoma,BIOLOGICAL: Blood sample|BIOLOGICAL: Cutaneous melanoma biopsy,ALL,"ADULT, OLDER_ADULT",NA,"Dermatology department, Paris, Ile De France, 75014, France"
NCT02355587,Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes,https://clinicaltrials.gov/study/NCT02355587,NO,Cutaneous Melanoma,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Sutter Health, Santa Rosa, California, 95403, United States|Elizabeth Liotta Dermatology, Frederick, Maryland, 21702, United States|University of Nevada, Las Vegas, Nevada, 89102, United States|South Carolina Skin Care Center, Greenville, South Carolina, 29607, United States"
NCT03313206,Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma,https://clinicaltrials.gov/study/NCT03313206,NO,Head and Neck Mucosal Melanomas,DRUG: Pembrolizumab|PROCEDURE: Surgery|RADIATION: IMRT|DRUG: Lenvatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Gustave Roussy, Villejuif, Val De Marne, 94805, France"
NCT05253872,The MELAcare Study: A New Method for Surveillance of Melanoma Patients,https://clinicaltrials.gov/study/NCT05253872,NO,Cutaneous Melanoma,OTHER: The MelaCare intervention,ALL,"ADULT, OLDER_ADULT",NA,"Herlev and Gentofte Hospital, Copenhagen, 2730, Denmark"
NCT02288897,PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT02288897,YES,Cutaneous Melanoma,"DRUG: PV-10 (10% rose bengal disodium)|DRUG: Dacarbazine, temozolomide or talimogene laherparepvec",ALL,"ADULT, OLDER_ADULT",PHASE3,"Sharp Memorial Hospital - Clinical Oncology Research, San Diego, California, 92123, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, United States|Washington University School of Medicine - Dermatology, Saint Louis, Missouri, 63110, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Atlantic Health System, Morristown, New Jersey, 07960, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, 27157, United States|Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma, 74146, United States|St Luke's University Hospital and Health Network, Easton, Pennsylvania, 18045, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, 17033, United States|M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Unité Cancéro-Dermatologie, Hôtel-Dieu CHU Nantes, Nantes, France|Institut Claudius Regaud, IUCT ONCOPOLE, Toulouse, 31059, France|Klinik für Dermatologie, Venerologie und Allergologie Charite Universitätsmedizin Berlin, Berlin, Germany|Klinik für Dermatologie Universitätsklinikum Essen Studienzentrum, Essen, Germany|Klinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Schleswig-Holstein Hautkrebszentrum, Kiel, Germany|Hautklinik Klinikum der Johannes Gutenberg Universität Hautkrebszentrum, Mainz, Germany|IRCCS Instituto Nazionale Tumori ""Fondazione Giovanni Pascale"", Napoli, Italy|Istituto Dermopatico dell'Immacolata (IDI IRCCS), Rome, Italy|Azienda Sanitaria Azienda Ospedaliera Universitaria Senese, Siena, Italy|Centro de Estudios y Prevención del Cancer A.C., Juchitán de Zaragoza, Oaxaca, 70000, Mexico|Neurociencias Estudios Clínicos S.C., Culiacán, Sinaloa, 80020, Mexico"
NCT03396952,Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma,https://clinicaltrials.gov/study/NCT03396952,YES,Stage III Cutaneous Melanoma|Stage IIIA Cutaneous Melanoma|Stage IIIB Cutaneous Melanoma|Stage IIIC Cutaneous Melanoma|Stage IV Cutaneous Melanoma,DRUG: Aspirin|BIOLOGICAL: Ipilimumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"University of Califonia, San Francisco, San Francisco, California, 94143, United States"
NCT04884997,A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma,https://clinicaltrials.gov/study/NCT04884997,NO,Malignant Melanoma,DRUG: toripalimab|DRUG: Temozolomide Injection,ALL,"ADULT, OLDER_ADULT",PHASE2,"Department of Medical Onocology, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310003, China"
NCT02355574,5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results,https://clinicaltrials.gov/study/NCT02355574,NO,Cutaneous Melanoma,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Northside Hospital, Atlanta, Georgia, 30342, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Saint Louis University, Saint Louis, Missouri, 63103, United States"
NCT04778449,"Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma",https://clinicaltrials.gov/study/NCT04778449,NO,Cutaneous Melanoma,OTHER: Medical Chart Review|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",,"M D Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT04274816,Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma,https://clinicaltrials.gov/study/NCT04274816,NO,Cutaneous Melanoma,DRUG: Tremelimumab,ALL,"ADULT, OLDER_ADULT",PHASE1,
NCT04253574,Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma,https://clinicaltrials.gov/study/NCT04253574,NO,Malignant Melanoma,DIAGNOSTIC_TEST: Imaging with 18F-FDG PET/CT and/or Ultrasound,ALL,"ADULT, OLDER_ADULT",,
NCT03842943,Neoadjuvant Combination Immunotherapy for Stage III Melanoma,https://clinicaltrials.gov/study/NCT03842943,NO,Cutaneous Melanoma,DRUG: Pembrolizumab|DRUG: Talimogene Laherparepvec,ALL,"ADULT, OLDER_ADULT",PHASE2,"University of Louisville, Louisville, Kentucky, 40202, United States"
NCT00424515,Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma,https://clinicaltrials.gov/study/NCT00424515,YES,Mucosal Melanoma|Acral/Lentiginous Melanoma|Chronically Sun Damaged Melanomas,DRUG: Imatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"University of Colorado at Denver Health Sciences Center, Denver, Colorado, 80045, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, 33612, United States|University of Chicago, Chicago, Illinois, 60637, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT03655756,pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT03655756,YES,"Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV",BIOLOGICAL: IFx-Hu2.0,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,"H. Lee Moffitt Cancer Center, Tampa, Florida, 33612, United States"
NCT04924413,L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT04924413,NO,Malignant Melanoma,DRUG: Tislelizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, 450008, China"
NCT01729663,"Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients",https://clinicaltrials.gov/study/NCT01729663,NO,Cutaneous Melanoma,"BIOLOGICAL: CSF470 vaccine, BCG, Molgramostim|DRUG: interferon alpha 2b",ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,"Instituto Médico Alexander Fleming, Buenos Aires, Capital Federal, 1426, Argentina"
NCT00991250,SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT00991250,NO,Malignant Melanoma,BIOLOGICAL: SentoClone®|DRUG: Temodal® or Dacarbazine Medac®,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,"Lunds Universitetssjukhus, Lund, Skåne, 22185, Sweden|Södersjukhuset, Stockholm, Stockholms Län, 11883, Sweden|Karolinska Sjukhuset, Stockholm, Stockholms Län, 17176, Sweden|Norrlands Universitetssjukhus, Umeå, Västerbottens Län, 90185, Sweden|Sahlgrenska Universitetssjukhuset, Göteborg, Västra Götalands Län, 41685, Sweden"
NCT04123470,A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma,https://clinicaltrials.gov/study/NCT04123470,NO,Malignant Melanoma,GENETIC: delolimogene mupadenorepvec|BIOLOGICAL: atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|Baylor St Luke's Medical Center, Houston, Texas, 77030, United States|Uppsala University Hospital, Uppsala, 75185, Sweden"
NCT04648163,Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma,https://clinicaltrials.gov/study/NCT04648163,NO,Malignant Melanoma,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Medical University of Graz, Graz, Styria, 8036, Austria"
NCT03649529,Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy,https://clinicaltrials.gov/study/NCT03649529,NO,Malignant Melanoma,BIOLOGICAL: GPA-TriMAR-T,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,"Hainan Cancer Hospital, Haikou, Hainan, 570100, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, 570100, China"
NCT00087477,A Pilot Study of Pivanex in Patients With Malignant Melanoma,https://clinicaltrials.gov/study/NCT00087477,NO,Malignant Melanoma,DRUG: Pivanex,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Mt. Sinai Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States"
NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT01247623,NO,Malignant Melanoma,BIOLOGICAL: GV1001,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Oslo University Hospital, Oslo, Postbox 4953, 0424, Norway"
NCT04593485,Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract,https://clinicaltrials.gov/study/NCT04593485,NO,Malignant Melanoma,DRUG: Camrelizumab for injection,FEMALE,"ADULT, OLDER_ADULT",PHASE2,"Fudan University Shanghai Cancer Center, Shanghai, Shanghai, 200032, China|Fudan University Shanghai Cancer Center, Shanghai, China"
NCT02068196,A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.,https://clinicaltrials.gov/study/NCT02068196,NO,Malignant Melanoma,PROCEDURE: Blood sampling for Pre-existing immunity|DRUG: Ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE4,"Haukeland University Hospital, Bergen, Norway|Nordland Hospital Bodø, Bodø, Norway|Sørlandet Hospital, Kristiansand, Kristiansand, Norway|Oslo University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, Tromsø, Norway|Trondheim University Hospital, St.Olavs Hospital, Trondheim, Norway|Ålesund Hospital, Ålesund, Norway"
NCT00323206,Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma,https://clinicaltrials.gov/study/NCT00323206,NO,Malignant Melanoma,BIOLOGICAL: IL-12p DNA|PROCEDURE: Intratumoral Electroporation,ALL,"ADULT, OLDER_ADULT",NA,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States"
NCT05200143,"Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma",https://clinicaltrials.gov/study/NCT05200143,NO,Refractory Cutaneous Melanoma,DRUG: Ipilimumab|DRUG: Nivolumab|DRUG: Cabozantinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Providence Portland Medical Center, Portland, Oregon, 97213, United States"
NCT00513604,Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00513604,YES,"Melanoma|Malignant Melanoma|Melanoma, Experimental|Experimental Melanomas",BIOLOGICAL: aldesleukin|BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: Cyclophosphamide|DRUG: Fludarabine phosphate|RADIATION: Total body irradiation,ALL,"ADULT, OLDER_ADULT",PHASE2,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT00498836,"Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma",https://clinicaltrials.gov/study/NCT00498836,NO,Malignant Melanoma,DRUG: CP-4055|DRUG: Sorafenib (Nexavar),ALL,"ADULT, OLDER_ADULT",PHASE2,"University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15232, United States|Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, 78229, United States|The Norwegian Radium Hospital, Oslo, NO-0310, Norway|Lund University Hospital, Lund, SE-221 85, Sweden|Umeå University Hospital, Umeå, Sweden|Uppsala University Hospital, Uppsala, SE-751 85, Sweden"
NCT01557114,Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT01557114,NO,Malignant Melanoma,DRUG: Ipilimumab|RADIATION: Radiotherapy,ALL,"ADULT, OLDER_ADULT",PHASE1,"Gustave Roussy Cancer Campus, Villejuif, Val de Marne, 94805, France|Institut Gustave Roussy, Villejuif, 94805, France"
NCT03116412,A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma,https://clinicaltrials.gov/study/NCT03116412,NO,Malignant Melanoma,PROCEDURE: CT or PET scans,ALL,"ADULT, OLDER_ADULT",NA,"Södra Älvsborgs sjukhus, Boras, Sweden|Mälarsjukhuset Eskilstuna, Eskilstuna, Sweden|Falu lasarett, Falun, Sweden|Gävle sjukhus, Gavle, Sweden|Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden|Helsingborgs lasarett, Helsingborg, Sweden|Länssjukhuset Ryhov, Jonkoping, Sweden|Länssjukhuset i Kalmar, Kalmar, Sweden|Centralsjukhuset i Karlstad, Karlstad, Sweden|Linköping University Hospital, Linkoping, Sweden|Skåne University Hospital, Malmö, Sweden|Örebro University Hospital, Orebro, Sweden|Skaraborgs sjukhus Skövde, Skovde, Sweden|Karolinska University Hospital, Stockholm, Sweden|Länssjukhuset Sundsvall, Sundsvall, Sweden|Uddevalla sjukhus, Uddevalla, Sweden|Umeå University Hospital, Umea, Sweden|Akademiska sjukhuset, Uppsala, Sweden|Västmanlands sjukhus Västerås, Vasteras, Sweden|Visby lasarett, Visby, Sweden"
NCT02275416,Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma,https://clinicaltrials.gov/study/NCT02275416,NO,Malignant Melanoma,DRUG: Ipilimumab|BIOLOGICAL: UV1 vaccine|BIOLOGICAL: GM-CSF,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Oslo University Hospital, Radiumhospitalet, Oslo, 0379, Norway"
NCT01227551,A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ),https://clinicaltrials.gov/study/NCT01227551,YES,Malignant Melanoma,BIOLOGICAL: Coxsackievirus A21 (CVA21),ALL,"ADULT, OLDER_ADULT",PHASE2,"Moores UCSD Cancer Center, La Jolla, California, 92093, United States|St Mary's Medical Center, San Francisco, California, 94117, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Oncology Specialists, SC, Niles, Illinois, 60714, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, 46260, United States|Atlantic Melanoma Center, Morristown, New Jersey, 07962, United States|Providence Cancer Center, Portland, Oregon, 97213, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, 75201, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States"
NCT04285749,Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas,https://clinicaltrials.gov/study/NCT04285749,NO,Malignant Melanoma,DRUG: Fluvastatin|OTHER: RNA-sequencing|OTHER: Gene expression profiling,ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,
NCT00535314,Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT00535314,NO,Malignant Melanoma,DRUG: RTA 402 Dose1|DRUG: RTA 402 Dose2,ALL,"ADULT, OLDER_ADULT",PHASE2,
NCT00963261,Quality of Life and Psychological Well-being in Patients With Malignant Melanoma,https://clinicaltrials.gov/study/NCT00963261,NO,Malignant Melanoma,BEHAVIORAL: psycho-oncological intervention,ALL,"ADULT, OLDER_ADULT",NA,"University Medical Center Freiburg, Department of Dermatology, Freiburg, 79104, Germany|University Medical Center Collogne, Department of Dermatology, Köln, 50937, Germany"
NCT00864253,A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma,https://clinicaltrials.gov/study/NCT00864253,YES,Malignant Melanoma,DRUG: ABI-007|DRUG: Dacarbazine,ALL,"ADULT, OLDER_ADULT",PHASE3,"University of Alabama at Birmingham, Birmingham, Alabama, 35243, United States|AZ Cancer Ctr, Scottsdale, Arizona, 85258, United States|Arizona Cancer Center, Tucson, Arizona, 85724, United States|Genesis Cancer Ctr - Hot Springs, Hot Springs, Arkansas, 71913, United States|University of Arkansa for Medical Sciences, Little Rock, Arkansas, 72205, United States|Tower Cancer Research Foundation, Beverly Hills, California, 90211, United States|San Diego Pacific Oncology and Hematology Associates, Encinitas, California, 92024, United States|Loma Linda University Cancer Center, Loma Linda, California, 92354, United States|University of Southern California/Norris Cancer Center, Los Angeles, California, 90033, United States|University of CA Los Angeles, Los Angeles, California, 90095, United States|St. Mary's Medical Center, San Francisco, California, 94117, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|Baptist Cancer Institute, Jacksonville, Florida, 32207, United States|Lakeland Regional Cancer Center, Lakeland, Florida, 33805, United States|University of Miami Hospital and Clincs/SCCC, Miami, Florida, 33136, United States|Waren Billhartz Cancer Center, Maryville, Illinois, 62062, United States|Indiana University, Indianapolis, Indiana, 46202, United States|IA Blood and Cancer Care, PLC, Cedar Rapids, Iowa, 52402, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Wayne State University, Detroit, Michigan, 48201, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|Saint Louis University, Saint Louis, Missouri, 63110, United States|St. John's Medical Research, Springfield, Missouri, 65807, United States|Nevada Cancer Institute, Las Vegas, Nevada, 89135, United States|Atlantic Melanoma Center, Morristown, New Jersey, 07962, United States|Piedmont Hematology, Winston-Salem, North Carolina, 27103, United States|OH State University Arthur G. James Cancer Hospital, Columbus, Ohio, 43210, United States|Integris Cancer Institute of OK, Oklahoma City, Oklahoma, 73142, United States|St. Luke's Hospital & Health Network, Bethlehem, Pennsylvania, 18015, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, 19131, United States|Mary Crowley Research Center, Dallas, Texas, 75246, United States|Univ of TX MD Anderson Cancer Ctr, Houston, Texas, 77030, United States|Univ of TX Med School at Houston, Houston, Texas, 77030, United States|Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, 79410, United States|Hope Oncology, Richardson, Texas, 75080, United States|Utah Cancer Specialist, Salt Lake City, Utah, 84106, United States|Univ. of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Evergreen Hematology & Oncology, Spokane, Washington, 99218, United States|Port Macquarie Base Hospital, Port Macquarie, New South Wales, 2444, Australia|Royal North Shore Hospital, Sydney, New South Wales, 2065, Australia|Sydney West Cancer Trials Centre/Westmead Hospital, Westmead, New South Wales, 2145, Australia|Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, 5000, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Alfred Hospital, Melbourne, Victoria, 3004, Australia|Sir Charles Gairdner Hospital, Nedlands Perth, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, 6000, Australia|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BCCA Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|BCCA, Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|BC Cancer Agency-Fraser Valley Ctr., Surrey, British Columbia, V3V 1Z2, Canada|BC Cancer Agency-Vancouver, Vancouver, British Columbia, V5Z4E6, Canada|BC Cancer Agency-Vancouver Island Ctr., Victoria, British Columbia, V8R 6V5, Canada|London Regional Cancer Program, London, Ontario, N6A 4L6, Canada|Credit Valley Hospital, Missiauga, Ontario, L5M 2N1, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|McGill University Dept. of Oncology Clinical Research Program, Montreal, Quebec, H2W 1S6, Canada|Hopital Saint Andre' CHU de Bordeaux, Bordeaux, 33075, France|Centre Hospitaller Universitaire de Grenoble, Grenoble Cedex 09, 38043, France|CHRU Hopital Claude Huriez, Lile Cedax, France|Hopital Dypuytren-CHU de Limoges, Limoges cedex, France|Centre Leon Berad, Lyon, France|Hopital Sainte Marguerite, Marseille Cedex 9, France|CHU Hopital Saint Eloi, Montepellier Cedex 5, France|Centre Regional Val d' Aurelle Paul Lamarque, Montpellier, 34298, France|Hopital de 1 Archet 2, Nice Cedex 3, 06200, France|Hopital Saint-Louis, Paris Cedex, France|Hopital Bichat, Paris, 75018, France|Groupe hospitalier Cochin-St. Vincent de Paul, Paris, France|Institut Gustave Roussy (IGR) Centre de Lutte Contre le Canc, Villejuif Cedex, 94805, France|Charite Universitaetsmedizin Berlin, Berlin, BE, 10117, Germany|Universitaetsklinkum Heidelberg, Heidelberg, BW, Germany|Universitaetsklinkum Heidelberg, Heidelber, BW, Germany|Universitaetsklinkum Tuebingen, Tuebingen, BW, 72076, Germany|Universitaetsklinkum Wuerzburg PS, Wuerzburg, BY, 97080, Germany|Universitaetsklinkum Hamburg-Eppendorf, Hamburg, HH, Germany|Univeritaetsklinkum Goettingen, Gottington, NI, Germany|Medizinische Hochschuke Hannover, Hannover, NI, 30625, Germany|St. Josef-Hospital, Bochum, Northwest, 44791, Germany|Universitaetsklinkum Essen, Essen, Northwest, Germany|Universitaetklinkum Koeln, Koln, Northwest, Germany|Universitaetsklinkum Schegwig-Holstein, Keil, SH, 24105, Germany|Universitaetsklinkum Dresden, Dresden, SN, Germany|UniversitawtsklinKum Jena, Jena, Strasse 35, 07743, Germany|Universitaesklinkum Leipzig, Leipzig, Germany|Universitaetsklinkum Mainz, Mainz, Germany|Istituto Tumori ""Giovanni Paolo II"", Bari, BA, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei T, Meldola, FC, 47014, Italy|IST-Istituto Nazionale per la Ricera sul Cancro, Genova, GE, 16132, Italy|Istituto Europeo di Oncologia, Milano, MI, 20141, Italy|Istituto Nazionale Tumori, Milano, MI, Italy|IOV-Instituto Oncologico IRCCS, Padova, PD, 35128, Italy|Azienda Ospedaliera Universitaria Sense, Siena, SI, 53100, Italy|Ist. Naz. per lo studio e la cura dei tumori G. Pascale, Napoli, 80131, Italy|Ospedale S. Chiara, Pisa, 56100, Italy|Medisch Centrum Alkmaar, Alkmaar, 1815, Netherlands|Rijnstate ziekenhuis Arnhem, Amhem, 6800TA, Netherlands|Erasmus MC ae"" Daniel den Hoed, Rotterdam, Netherlands|H Clinic i Provincial, Barcelona, 08036, Spain|H CLINIC I Provincial, Barcelona, Spain|H Clinico San Carlos, Madrid, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, 08208, Spain|Broomfield Hospital, Chelmsford, Essex, CM1 7ET, United Kingdom|Velindre Hospital, Cardiff, Glam, CF14 2TL, United Kingdom|St. George's Hospital, London, GT Lon, SW12 ORE, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, Nott, NG5 1PB, United Kingdom|Singleton Hospital, Sothwest Wales Inst., Swansea, S Glam, SA28QA, United Kingdom|Univ Hospital of North Staffordshire, Stroke On Kent, Staffs, ST4 6QB, United Kingdom|Weston Park Hospital, Sheffield, Syorks, S10 2SJ, United Kingdom|Newcross Hospital, Wolverhampton, Wstmid, SV10 0QP, United Kingdom|Royal Marsden Hospital London, London, SW3 6JJ, United Kingdom"
NCT00179608,Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy,https://clinicaltrials.gov/study/NCT00179608,NO,Malignant Melanoma,DRUG: CC-5013,ALL,"ADULT, OLDER_ADULT",PHASE1,"MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States"
NCT03860883,Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT03860883,NO,"Cutaneous Melanoma, Stage II",PROCEDURE: Wide Local Excision = 1cm Margin|PROCEDURE: Wide Local Excision = 2cm Margin,ALL,"ADULT, OLDER_ADULT",PHASE3,"University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, 36604, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Mayo Clinic Phoenix, Phoenix, Arizona, 85054, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|The Angeles (Cedars-Sinai Medical Center and its Affiliates), Los Angeles, California, 90048-1804, United States|UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Stanford Cancer Institute, Palo Alto, California, 94304, United States|Kaiser Permanente - Vallejo Medical Center, Vallejo, California, 94589, United States|Kaiser Permanente - Walnut Creek Medical Center, Walnut Creek, California, 94596, United States|Smilow Hospital Care Center, Guilford, Guilford, Connecticut, 06437, United States|Yale University, New Haven, Connecticut, 06520, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, 20007, United States|MedStar Washington Hospital Center, Washington, District of Columbia, 20010, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, 32207, United States|Mayo Clinic in Florida, Jacksonville, Florida, 32224, United States|Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, 33805, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, 33612, United States|Moffitt Cancer Center, Magnolia Campus, Tampa, Florida, 33612, United States|Emory University Hospital Midtown, Atlanta, Georgia, 30308, United States|Emory University, Atlanta, Georgia, 30322, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, 30342, United States|Northside Hospital Atlanta, Atlanta, Georgia, 30342, United States|Northside Hospital Cancer Institute, Atlanta, Georgia, 30342, United States|Nancy N and JC Lewis Cancer & Research Pavilion St. Joseph's/Candler, Savannah, Georgia, 31405, United States|Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, 60115, United States|Northwestern University, Evanston, Illinois, 60208, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, 60134, United States|Northwestern Medicine Cancer Center Lake Forest Hospital, Lake Forest, Illinois, 60045, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, 60068, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, 60555, United States|University of Kansas Hospital - Indian Creek Campus, Overland Park, Kansas, 66211, United States|University of Kansas Hospital- Westwood Cancer Center, Westwood, Kansas, 66205, United States|University of Kentucky, Lexington, Kentucky, 40506, United States|MedStar Franklin Square Medical Center, Baltimore, Maryland, 21237, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, 49503, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, 49503, United States|West Michigan Cancer Centre, Kalamazoo, Michigan, 49007, United States|Siteman Cancer Centre, Barnes Jewish West County, Creve Coeur, Missouri, 63141, United States|University of Kansas Cancer Center, Kansas City, Missouri, 64154, United States|Cox South Hospital, Springfield, Missouri, 65807, United States|Nebraska Medicine - Bellevue, Bellevue, Nebraska, 68123, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, 68118, United States|University of Nebraska Medicine, Omaha, Nebraska, 68198, United States|Cooperman Barnabas Medical Center, Livingston, New Jersey, 07039, United States|Rutgers Cancer Institute of New Jersey, Piscataway, New Jersey, 08854, United States|Northwell Health Imbert Cancer Center, Bay Shore, New York, 11706, United States|Roswell Park Cancer Institute, Buffalo, New York, 14203, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, 11042, United States|NYU Langone Medical Center (Winthrop Hospital), Mineola, New York, 11501, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, 10016, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, 12601, United States|University of Rochester, Rochester, New York, 14642, United States|State University of New York Upstate Medical University, Syracuse, New York, 13210, United States|State University of New York Upstate Medical Center-Community Campus, Syracuse, New York, 13215, United States|Wilmont Cancer Institute at Webster, Webster, New York, 14580, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|East Carolina University, Greenville, North Carolina, 27858, United States|Sanford Broadway Medical Centre, Fargo, North Dakota, 58102, United States|Sanford Roger Maris Cancer Centre, Fargo, North Dakota, 58102, United States|University Hospitals Avon Health Center, Avon, Ohio, 44011, United States|Miami Valley Hospital South, Centerville, Ohio, 45459, United States|University Hospitals Geauga Medical Center, Chardon, Ohio, 44024, United States|University of Cincinnati, Cincinnati, Ohio, 45219, United States|University Hospitals Cleveland Medical Centre, Cleveland, Ohio, 44106, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University Hospitals Chagrin Highlands Medical Centre, Orange Village, Ohio, 44122, United States|West Chester Hospital (OH394), West Chester, Ohio, 45069, United States|University Hospitals St. John Medical Center, Westlake, Ohio, 44145, United States|OUHSC Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Mercy Health Center - Oncology Hematology, Oklahoma City, Oklahoma, 73120-8362, United States|Kaiser Sunnyside Medical Center, Clackamas, Oregon, 97015, United States|Kaiser Permanente Northwest - Oncology Clinic, Portland, Oregon, 97227, United States|St. Luke's University Health Network - Allentown Cancer Center, Allentown, Pennsylvania, 18104, United States|St Luke's University Health Network, Bethlehem Campus, Bethlehem, Pennsylvania, 18015, United States|St Luke's University Health Network, Anderson Campus, Easton, Pennsylvania, 18045, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|St Luke's University Health Network Quakertown Campus, Quakertown, Pennsylvania, 18951, United States|St. Luke's University Health Network - Upper Bucks, Quakertown, Pennsylvania, 18951, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, 18840, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Univ of Texas Health Science Center at San Antonio, San Antonio, Texas, 78284-7884, United States|Intermountain Medical Center, Murray, Utah, 84157, United States|Huntsman Cancer Institute (The University of Utah), Salt Lake City, Utah, 84112, United States|University of Vermont Medical Center, Burlington, Vermont, 05401, United States|University of Vermount and Sate Agricultural College, Burlington, Vermont, 05405, United States|University of Virginia Health System, Charlottesville, Virginia, 22903, United States|VCU Massey Cancer Center Peninsula Cancer Institute, Newport News, Virginia, 23601, United States|VCU Massey Cancer Center, Richmond, Virginia, 23298, United States|Carilion Roanoke Memorial Hospital, Roanoke, Virginia, 24014, United States|VCU Massey Cancer Center Affiliate Valley Health, Winchester, Virginia, 22601, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, 53792, United States|Marshfield Medical Center - Marshfield, Marshfield, Wisconsin, 54449, United States|Aurora St Luke's Medical Center, Milwaukee, Wisconsin, 53215, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Calvary Public Hospital Bruce, Bruce, Australian Capital Territory, 2617, Australia|The Canberra Hospital, Garran, Australian Capital Territory, 2605, Australia|Westmead Hospital, Sydney, New South Wales, 2145, Australia|Melanoma Institute Australia, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia|Robina Hospital, Gold Coast, Queensland, 4226, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Tom Baker Cancer Centre, Calgary, Alberta, T2N 4N2, Canada|BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, L4M 6M2, Canada|Hamilton Health Sciences Centre, Hamilton, Ontario, L8V 1C3, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, K1Y 4E9, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|UHN - Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2C1, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, H1T 2M4, Canada|Hotel-Dieu de Quebec, Québec City, Quebec, G1R2J6, Canada|IOV Istituto Oncologico Veneto IRCCS-Padova, Padova, 35128, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy|AOU Città della Salute e della Scienza di Torino, Torino, 10126, Italy|Flevo Hospital, Almere, Flevoland, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Gelderland, 6716 RP, Netherlands|Gelre Hospital, Zutphen, Gelderland, 7207 AE, Netherlands|University Medical Centre Groningen, Groningen, 9713, Netherlands|Zuyderland Medical Center, Heerlen, 6419, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|North Shore Hospital, Auckland, 0620, New Zealand|Sahlgrenska University Hospital, Gothenburg, Sweden|Central Hospital Kristianstad, Kristianstad, 29133, Sweden|University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 2TH, United Kingdom|Royal Cornwall Hospital NHS Trust, Truro, Cornwall, TR1 3LJ, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, East Yorkshire, HU3 2JZ, United Kingdom|MID & South Essex NHS Foundation Trust, Westcliff on Sea, Essex, SS0 0RY, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, OX3 9DU, United Kingdom|Imperial College Healthcare NHS Trust, London, The Bays, W2 1NY, United Kingdom|Queen Victoria Hospital NHS Foundation Trust, East Grinstead, West Sussex, RH19 3DZ, United Kingdom|North Bristol NHS Trust, Bristol, BS10 5NB, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, United Kingdom|St. Helens & Knowsley Teaching Hospitals NHS Trust, Liverpool, United Kingdom|The Royal Marsden Hospital NHS Foundation Trust, London,, SW3 6JJ, United Kingdom|Royal Free London NHS Foundation Trust, London, NW3 2QG, United Kingdom|Guy's and St Thomas's NHS Foundation Trust, of St Thomas' Hospital, London, SE1 7EH, United Kingdom|St George's University Hospitals NHS Foundation Trust, London, SW17 0QT, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital, Middlesbrough, TS4 3BW, United Kingdom|Norfolk and Norwich University Hospital NHS Trust, Norwich, NR47UY, United Kingdom|Nottingham University Hospitals, NHS Trust, Trust HQ, City Hospital, Nottingham, NG5 1PB, United Kingdom"
NCT01211262,Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma,https://clinicaltrials.gov/study/NCT01211262,YES,Malignant Melanoma,DRUG: IMCgp100,ALL,"ADULT, OLDER_ADULT",PHASE1,"The Angeles Clinic, Los Angeles, California, 90025, United States|Yale Cancer Center, New Haven, Connecticut, 06520-8028, United States|Memorial Slone Kettering Cancer Center, New York, New York, 10065, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Queen Elizabeth Hospital, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|The Beatson Institute, Glasgow, United Kingdom|St James Hospital, Leeds, United Kingdom|NIHR Biomedical Research Centre, Oxford, United Kingdom"
NCT00300612,Vaccine Treatment for Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT00300612,NO,Malignant Melanoma,BIOLOGICAL: HyperAcute-Melanoma Vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States"
NCT04789421,"Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management",https://clinicaltrials.gov/study/NCT04789421,NO,Cutaneous Melanoma,"DEVICE: Clinical, dermoscopy and Reflective confocal microscopy evaluations|DEVICE: Clinical, dermoscopy evaluations",ALL,"ADULT, OLDER_ADULT",NA,
NCT01253096,Intratumoral Application of L19IL2 in Patients With Malignant Melanoma,https://clinicaltrials.gov/study/NCT01253096,NO,Malignant Melanoma,DRUG: Intratumoral injections of L19IL2,ALL,"ADULT, OLDER_ADULT",PHASE2,"Universitätsklinik Graz, Graz, Austria|Medizinischen Hochschule Hannover, Hannover, Germany|University Hospital, Tuebingen, Germany"
NCT01588847,Anesthesia and Cancer Recurrence im Malignant Melanoma,https://clinicaltrials.gov/study/NCT01588847,NO,Malignant Melanoma,"PROCEDURE: Spinal anesthesia with Bupivacaine hyperbar 0.5 %|PROCEDURE: General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane",ALL,"ADULT, OLDER_ADULT",NA,"Fachklinik Hornheide, Department of Anesthesiology, Intensive Care and Pain Therapy, Münster, D-48157, Germany"
NCT00142454,NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting),https://clinicaltrials.gov/study/NCT00142454,YES,Malignant Melanoma,DRUG: Imiquimod|BIOLOGICAL: NY-ESO-1 protein,ALL,"ADULT, OLDER_ADULT",PHASE1,"NYU Cancer Institute, New York, New York, 10016, United States"
NCT03278665,4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy,https://clinicaltrials.gov/study/NCT03278665,NO,Malignant Melanoma,DRUG: 4SC-202 in combination with Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Universitätsklinikum Essen, Essen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum der Universität München, München, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Istituto Nazionale Tumori Fondazione ""G. Pascale"", Napoli, Italy"
NCT02272855,A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,https://clinicaltrials.gov/study/NCT02272855,NO,Malignant Melanoma,BIOLOGICAL: HF10 plus Ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"Clinical Site, San Francisco, California, 94115, United States|Clinical Site, Atlanta, Georgia, 30322, United States|Clinical Site, Portland, Oregon, 97239, United States|Clinical Site, Bethlehem, Pennsylvania, 18015, United States|Clinical Site, Hershey, Pennsylvania, 17033, United States|Clinical Site, Dallas, Texas, 75230, United States|Clinical Site, Houston, Texas, 77030, United States|Clinical Site, Salt Lake City, Utah, 84112, United States"
NCT02535078,Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT02535078,NO,Malignant Melanoma,DRUG: Tebentafusp (IMCgp100)|DRUG: durvalumab|DRUG: tremelimumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 15213, United States"
NCT06294379,Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy,https://clinicaltrials.gov/study/NCT06294379,NO,Malignant Melanoma,,ALL,"ADULT, OLDER_ADULT",,"Odense University Hospital, Odense C, 5000, Denmark"
NCT02968680,Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT02968680,NO,Cutaneous Melanoma|Melanoma,PROCEDURE: Sentinel Lymph Node Biopsy|DEVICE: Ultrasonography|DRUG: Sonazoid,ALL,"ADULT, OLDER_ADULT",PHASE1,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States"
NCT04547946,Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib),https://clinicaltrials.gov/study/NCT04547946,NO,Malignant Melanoma,DRUG: dabrafenib + trametinib,ALL,"ADULT, OLDER_ADULT",,"Novartis Investigative Site, Coimbra, Center, 3000-075, Portugal|Novartis Investigative Site, Oporto, North, 4200-319, Portugal"
NCT01942603,Minimal SN Tumor Burden,https://clinicaltrials.gov/study/NCT01942603,NO,Cutaneous Melanoma,,ALL,"ADULT, OLDER_ADULT",,"U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium|CHRU de Lille, Lille, France|CHU de Nice - Hopital De L'Archet, Nice, France|Institut Gustave Roussy, Paris, France|Charite - Universitaetsmedizin Berlin - Campus Mitte, Berlin, Germany|Universitaetsklinikum - Essen, Essen, Germany|UniversitaetsMedizin Mannheim, Mannheim, Germany|Istituto Europeo di Oncologia, Milan, Italy|Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy|Istituto Oncologico Veneto IRCCS - Ospedale Busonera, Padova, Italy|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Erasmus MC Cancer Institute - location Daniel den Hoed, Rotterdam, Netherlands|Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw, Poland|The Institute Of Oncology, Ljubljana, Slovenia|Hospital Clinic Universitari, Barcelona, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Cambridge University Hospital NHS - Addenbrookes Hospital, Cambridge, United Kingdom|Guy's and St Thomas' NHS - St Thomas Hospital, London, United Kingdom|St George's Hospital NHS Trust, London, United Kingdom|Norfolk And Norwich Hospital, Norwich, United Kingdom|St Helens & Knowsley NHS Trust - Whiston Hospital, Prescott, United Kingdom"
NCT01278940,Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT01278940,NO,Malignant Melanoma,BIOLOGICAL: Dendritic Cells (DC) malignant melanoma|PROCEDURE: IL-2,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,
NCT03843593,A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery,https://clinicaltrials.gov/study/NCT03843593,NO,Cutaneous Melanoma,BEHAVIORAL: Demographics Questionnaire|BEHAVIORAL: Adjuvant Treatment Beliefs Scale10|BEHAVIORAL: Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|BEHAVIORAL: Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|BEHAVIORAL: Decisional Regret14|BEHAVIORAL: Clinician Preference for Treatment,ALL,"ADULT, OLDER_ADULT",,"Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States"
NCT00145158,Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT00145158,YES,Malignant Melanoma,BIOLOGICAL: 8 HLA-A2-restricted peptides and Montanide ISA51|BIOLOGICAL: 8 HLA-A2-restricted peptides and CpG 7909,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Clinique Universitaires St-Luc, Brussels, B-1200, Belgium|Ludwig Institute for Cancer Research, Brussels, B-1200, Belgium"
NCT00235482,Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02),https://clinicaltrials.gov/study/NCT00235482,NO,Malignant Melanoma,DRUG: Coxsackievirus A21,ALL,"ADULT, OLDER_ADULT",PHASE1,"Melanoma Unit, Mater Misericordiae Hospital, Newcastle, New South Wales, 2298, Australia"
NCT03628417,Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases,https://clinicaltrials.gov/study/NCT03628417,YES,Cutaneous Melanoma,PROCEDURE: Calcium Electroporation|PROCEDURE: Bleomycin based electrochemotherapy,ALL,"ADULT, OLDER_ADULT",NA,
NCT00358319,Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma,https://clinicaltrials.gov/study/NCT00358319,NO,Malignant Melanoma,DRUG: Karenitecin|DRUG: Valproic Acid,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States"
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,https://clinicaltrials.gov/study/NCT02650492,NO,Melanoma|Malignant Melanoma,DEVICE: Immunostimulating Interstitial Laser Thermotherapy,ALL,"ADULT, OLDER_ADULT",NA,"Karolinska University Hospital Solna, Stockholm, 17176, Sweden"
NCT00087776,Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma,https://clinicaltrials.gov/study/NCT00087776,NO,Malignant Melanoma,DRUG: Chemotherapy,ALL,"ADULT, OLDER_ADULT",NA,"Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, 19403, United States"
NCT00729950,Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,https://clinicaltrials.gov/study/NCT00729950,NO,Malignant Melanoma,BIOLOGICAL: MDX-010,ALL,"ADULT, OLDER_ADULT",PHASE1,"Arizona Cancer Center, Tucson, Arizona, 85724-5024, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Piedmont Oncology Specialists, Charlotte, North Carolina, 28207, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States"
NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma",https://clinicaltrials.gov/study/NCT01137006,YES,Malignant Melanoma,BIOLOGICAL: IMC-20D7S (Cohort 1A)|BIOLOGICAL: IMC-20D7S (Cohort 2A)|BIOLOGICAL: IMC-20D7S (Cohort 3A)|BIOLOGICAL: IMC-20D7S (Cohort 4A)|BIOLOGICAL: IMC-20D7S (Cohort 1B)|BIOLOGICAL: IMC-20D7S (Cohort 2B)|BIOLOGICAL: IMC-20D7S (Cohort 3B),ALL,"ADULT, OLDER_ADULT",PHASE1,"ImClone Investigational Site, Boston, Massachusetts, 02114, United States|ImClone Investigational Site, New York, New York, 10021, United States"
NCT04217382,Pre Transplantation Melanoma,https://clinicaltrials.gov/study/NCT04217382,NO,Malignant Melanoma,OTHER: patient with melanoma pre transplantation,ALL,"ADULT, OLDER_ADULT",,"service de dermatologie - hopital Edouard Herriot, Lyon, Rhone, 69003, France"
NCT00327600,Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT00327600,NO,Malignant Melanoma,DRUG: imexon|DRUG: DTIC,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,"Investigational Site 009, Los Angeles, California, 90033, United States|Investigational Site 002, Santa Monica, California, 90404, United States|University of CO Anschutz Cancer Pavilion, Aurora, Colorado, 80010, United States|US Oncology Orlando, Cancer Centers of FL, Ocoee, Florida, 34761, United States|US Oncology Albany, New York Oncology, Albany, New York, 12208, United States|US Oncology Kettering, Kettering, Ohio, 45409, United States|US Oncology Greenville, Cancer Centers of the Carolinas, Greenville, South Carolina, 29615, United States|US Oncology, Tyler Cancer Center, Tyler, Texas, 75702, United States|Investigational Site 012, Salt Lake City, Utah, 84112, United States|US Oncology, Virginia Oncology Assoc, Norfolk, Virginia, 23502, United States|US Oncology Spokane, Cancer Care Northwest, Spokane, Washington, 99218, United States"
NCT01636960,A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370),https://clinicaltrials.gov/study/NCT01636960,YES,Malignant Melanoma,BIOLOGICAL: PegIFN alfa-2b,ALL,"ADULT, OLDER_ADULT",PHASE1,
NCT03538314,UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma,https://clinicaltrials.gov/study/NCT03538314,NO,Malignant Melanoma,DRUG: UV1|DRUG: GM-CSF,ALL,"ADULT, OLDER_ADULT",PHASE1,"John Wayne Cancer Center, Santa Monica, California, 90404, United States|University of Iowa Carver College of Medicine, Iowa City, Iowa, 52242, United States|St. Luke's University Health Network, Easton, Pennsylvania, 18045, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States"
NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,https://clinicaltrials.gov/study/NCT01138410,NO,Malignant Melanoma,BIOLOGICAL: SCIB1,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Department of Medical Oncology, The Royal Surrey County Hospital, Guildford, Surrey, GU2 7XX, United Kingdom|St James' Institute of Oncology, Leeds, LS9 7TF, United Kingdom|Christie Hospital, Manchester, M20 4BX, United Kingdom|Department of Clinical Oncology, City Hospital, Nottingham, NG5 1PB, United Kingdom|Department of Medical Oncology, Southampton General Hospital, Southampton, SO16 6YD, United Kingdom"
NCT01124734,High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma,https://clinicaltrials.gov/study/NCT01124734,YES,Malignant Melanoma,DRUG: Interleukin-2|DRUG: Temozolomide,ALL,"ADULT, OLDER_ADULT",PHASE2,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States"
NCT01455259,Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors,https://clinicaltrials.gov/study/NCT01455259,NO,Malignant Melanoma,BIOLOGICAL: AdCD40L,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Uppsala University Hospital, Uppsala, 75185, Sweden"
NCT00963664,Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma,https://clinicaltrials.gov/study/NCT00963664,NO,Melanoma|Malignant Melanoma,DRUG: lovastatin|DRUG: interferon alfa-2b,ALL,"ADULT, OLDER_ADULT",PHASE2,"NeoPlas Innovation, Nashville, Tennessee, 37027, United States"
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",https://clinicaltrials.gov/study/NCT01696045,YES,Malignant Melanoma,BIOLOGICAL: Ipilimumab,ALL,CHILD,PHASE2,"Phoenix Children'S Hospital, Phoenix, Arizona, 85016, United States|Childrens Hospital Of La, Los Angeles, California, 90027, United States|Children'S Hospital Of Orange County, Orange, California, 92868, United States|Children'S Hospital Colorado, Aurora, Colorado, 80045, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|James Whitcomb Riley Hospital For Children, Indianapolis, Indiana, 46202, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|University Of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|St. Jude Children'S Research Hospital, Memphis, Tennessee, 38105, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, 77030, United States|Primary Children'S Medical Center, Salt Lake City, Utah, 84113, United States|University Of Utah, Salt Lake City, Utah, 84113, United States|Local Institution, Gent, 9000, Belgium|Local Institution, Copenhagen, 2100, Denmark|Local Institution, Lyon, 69008, France|Local Institution, Marseille Cedex 5, 13385, France|Local Institution, Nantes Cedex 1, 44093, France|Local Institution, Villejuif Cedex, 94805, France|Local Institution, Dortmund, 44137, Germany|Local Institution, Erlangen, 91054, Germany|Local Institution, Hamburg, 20246, Germany|Local Institution, M?nster, 48149, Germany|Local Institution, Munster, 48149, Germany|Local Institution, Mexico, D.F, 02990, Mexico|Local Institution, Df, Distrito Federal, 06720, Mexico|Local Institution, Leon, Guanajato, Guanajuato, 37000, Mexico|Local Institution, Esplugues de Llobregat- Barcelona, 08950, Spain|Local Institution, Bristol, Avon, BS2 8BJ, United Kingdom|Local Institution, Newcastle, Northumberland, NE1 4LP, United Kingdom|Local Institution, Sutton, Surrey, SM2 5PT, United Kingdom"
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,https://clinicaltrials.gov/study/NCT01264081,YES,Malignant Melanoma,DRUG: Lapatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States"
NCT00145041,Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction,https://clinicaltrials.gov/study/NCT00145041,YES,Malignant Melanoma,DRUG: Vincristine Sulfate Liposomes Injection,ALL,"ADULT, OLDER_ADULT",PHASE1,"University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT03034395,Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma,https://clinicaltrials.gov/study/NCT03034395,NO,Malignant Melanoma,PROCEDURE: Wide Local Excision,ALL,"ADULT, OLDER_ADULT",NA,"University of Kansas Medical Center, Kansas City, Kansas, 66160, United States"
NCT02537600,Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis,https://clinicaltrials.gov/study/NCT02537600,NO,Malignant Melanoma,DRUG: Cobimetinib + Vemurafenib combination treatment,ALL,"ADULT, OLDER_ADULT",PHASE2,"CHU de Bordeaux, Bordeaux, 33000, France|CHU Ambroise Paré, Boulogne, 92104, France|CHU Brest - Hôpital Morvan, Brest, France|CHU Caen - Hôpital Clémenceau, Caen, 14033, France|Hôpital Henri Mondor, Creteil, 94010, France|CHU de Dijon, Dijon, France|CHU Albert Michallon, Grenoble, 38014, France|Centre Hospitalier du Mans, Le Mans, 72037, France|CHRU Lille, Lille, 59037, France|Centre Hospitalier Lyon Sud, Lyon, 69495, France|CHU de Nantes, Nantes, 44093, France|Groupe Hospitalier l'Archet, Nice, 06202, France|Hôîtal St louis, Paris, 75010, France|Hôpital Cochin, Paris, 75014, France|Hôpital Bichat, Paris, 75018, France|Centre Eugène Marquis, Rennes, 35042, France|CHU Tours, Tours, 37044, France"
NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,https://clinicaltrials.gov/study/NCT01024231,YES,Malignant Melanoma,DRUG: BMS-936558 (MDX1106-04)|DRUG: Ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"Yale University School Of Medicine, New Haven, Connecticut, 06520, United States|Medstar Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|Memorial Sloan Kettering Nassau, New York, New York, 11065, United States|Hillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, 15232, United States"
NCT02223884,A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy,https://clinicaltrials.gov/study/NCT02223884,NO,Malignant Melanoma,DRUG: docetaxel 35mg/m2|DRUG: Carboplatin AUC3,ALL,"ADULT, OLDER_ADULT",PHASE2,"Severance Hospital, Seoul, 120-752, Korea, Republic of"
NCT00733798,A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma,https://clinicaltrials.gov/study/NCT00733798,NO,Melanoma|Malignant Melanoma|Metastatic Melanoma,DRUG: 131I-TM601,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Lacks Cancer Center, Grand Rapids, Michigan, 49503, United States|New York University School of Medicine, New York, New York, 10016, United States|Mary Crowley Cancer Center, Dallas, Texas, 75246, United States"
NCT02673970,Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT02673970,NO,Malignant Melanoma,,ALL,"ADULT, OLDER_ADULT",,"UZ Brussel, Jette, Brabant, 1090, Belgium|UZ Brussel, Jette, Brussels, 1090, Belgium"
NCT05089370,Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma,https://clinicaltrials.gov/study/NCT05089370,NO,Malignant Melanoma,COMBINATION_PRODUCT: Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"University of Colorado Hospital, Aurora, Colorado, 80045, United States"
NCT01543464,Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients,https://clinicaltrials.gov/study/NCT01543464,NO,Malignant Melanoma,DRUG: Chemotherapy: Temozolomide,ALL,"ADULT, OLDER_ADULT",PHASE2,"Trine Zeeberg Iversen, Brønshøj, Copenhagen, 2700, Denmark"
NCT05675709,Enhancing Skin Cancer Early Detection and Treatment in Primary Care,https://clinicaltrials.gov/study/NCT05675709,NO,Cutaneous Melanoma,BEHAVIORAL: Training and Education,ALL,"ADULT, OLDER_ADULT",NA,"OHSU Knight Cancer Institute, Portland, Oregon, 97239, United States"
NCT00539591,Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma,https://clinicaltrials.gov/study/NCT00539591,YES,Malignant Melanoma,DRUG: Peginterferon alfa-2b|DRUG: Temozolomide|DRUG: Recombinant interferon alfa-2b,ALL,"CHILD, ADULT",PHASE2,"Rady Children's Hospital, San Diego, California, 92123, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States|The Children's Cancer Hospital at UT M.D. Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT02889861,IMCgp100-401 Rollover Study,https://clinicaltrials.gov/study/NCT02889861,YES,Malignant Melanoma,DRUG: IMCgp100,ALL,"ADULT, OLDER_ADULT",PHASE2,"Memorial Slone Kettering Cancer Center, New York, New York, 10065, United States|Dept of Oncology & Haematology, Churchill Hospital, Oxford, Oxfordshire, OX3 7LJ, United Kingdom|Dept of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, G12 OYN, United Kingdom"
NCT01898039,Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients,https://clinicaltrials.gov/study/NCT01898039,NO,Malignant Melanoma,BIOLOGICAL: A2/4-1BBL melanoma vaccine|PROCEDURE: DNP sensititzation|DRUG: Cyclophosphamide,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE1|PHASE2,"Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, 91120, Israel"
NCT03448666,ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases,https://clinicaltrials.gov/study/NCT03448666,NO,Malignant Melanoma,COMBINATION_PRODUCT: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"IEO Istituto Europeo di Oncologia, Milan, 20141, Italy"
NCT02071940,PLX3397 KIT in Acral aNd mucOsal Melanoma,https://clinicaltrials.gov/study/NCT02071940,NO,Malignant Melanoma,DRUG: PLX3397,ALL,"ADULT, OLDER_ADULT",PHASE2,"The Christie NHS Foundation Trust, Manchester, Greater Manchester, M20 4BX, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, Scotland, G12 OXH, United Kingdom|Abertawe Bro Morgannwg University Health Board, Singleton Hospital, Swansea, Wales, SA2 8QA, United Kingdom|St James' University Hospital, Leeds, Yorkshire, LS9 7TF, United Kingdom|Cancer Clinical Trials Centre- Weston Park Hospital, Sheffield, Yorkshire, S10 2SJ, United Kingdom|Cambridge University Hospitals NHS FT - Addenbrookes Hospital, Cambridge, CB2 0QQ, United Kingdom|The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, United Kingdom|Oxford University Hospitals NHS Trust- Churchill Hospital, Oxford, OX3 7LE, United Kingdom"
NCT03563729,Melanoma Metastasized to the Brain and Steroids,https://clinicaltrials.gov/study/NCT03563729,NO,Malignant Melanoma,DRUG: Pembrolizumab Injection [Keytruda]|DRUG: Ipilimumab Injection [Yervoy]|DRUG: Nivolumab Injection [Opdivo]|DRUG: Encorafenib|DRUG: Binimetinib|DRUG: Dabrafenib|DRUG: Trametinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Herlev Universityhospital, Herlev, Hovedstaden, 2730, Denmark|Aarhus Universityhospital, Aarhus, Midt, 8000, Denmark|Odense Universityhospital, Odense, Syd, 5000, Denmark"
NCT00911443,"Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma",https://clinicaltrials.gov/study/NCT00911443,YES,Malignant Melanoma,BIOLOGICAL: Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|BIOLOGICAL: Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|BIOLOGICAL: Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|BIOLOGICAL: Dacarbazine + Thymosin-alpha-1 3.2 mg|DRUG: Dacarbazine + Interferon alpha,ALL,"ADULT, OLDER_ADULT",PHASE2,"CHU de Grenoble Hopital Albert Michallon Service de Dermatologie, La Tronche, 38043, France|CHU de Limoges Hopital Dupuytren Service de Dermatologie, Limoges, 87042, France|Hopital Saint-Eloi Service de Dermatologie, Montpellier, 34295, France|Centre Eugene Marquis Departement d'Oncologie Medicale, Rennes, 35042, France|Hopital Purpan Service de Dermatologie, Toulouse, 31059, France|Klinik fur Dermatologie und Allergologie der RWTH Aachen, Aachen, 52074, Germany|Klinik fur Dermatologie, Venerologie und Allergologie des Campus Charitè Mitte, Berlin, 10117, Germany|Elbeklinikec Buxtehude Dermatologische Zentrum Abteilung fur Dermato-Onkologie, Buxtehude, 21614, Germany|Zentrum fur Dermatologie und Veneralogie Klinik der Johann-Wolfgang-Goethe-Universitat, Frankfurt, 60590, Germany|Klinikum Hannover, Hautklinik Linden, Hannover, D-30449, Germany|Universitatsklinikum Schlewig-Holstein Klinik fur Dermatologie, Veneralogie und Allergologie Universitats-Hautklinik Kiel, Kiel, 24105, Germany|Universitatsklinik fur Dermatologie und Venerologie Otto-von-Guericke-Universitat Magdeburg, Magdeburg, 39120, Germany|Dermatologische Klinik der Universitat Tubingen, Tubingen, 72076, Germany|Orszagos Bor-es Nemikortani Intezet, Budapest, H-1085, Hungary|Orszagos Onkologiai Intezet Borgyogyaszat, Budapest, H-1122, Hungary|Petz Aladar Megyei Korhaz, Borgyogyaszat, Gyor, H-9024, Hungary|Miskolc Megyei Korhaz Borgyogyaszat, Miskolc, H-3501, Hungary|Pecsi Egyetem Borgyogyaszati Klinika, Pecs, H-7600, Hungary|Szegedi Egyetem Borgyogyaszati Klinika, Szeged, H-6701, Hungary|Ospedale SS Trinità Oncologia, Sora, Frosinone, 03039, Italy|Ospedale San Vincenzo U.O. Oncologia Medica, Taormina, Messina, 98039, Italy|UO Complessa Aziendale Nettuno/Albano/Frascati Day-Hospital di Oncologia Ospedale S. Giuseppe, Albano Laziale, Roma, 00041, Italy|Ospedale PF Calvi Dipartimento di Oncologia, Noale, Venezia, 30033, Italy|ASL 1 Servizio di Oncologia, Agrigento, Italy|Azienda Ospedaliera S. Elia, UO di Oncologia, Caltanissetta, 93100, Italy|Azienda Ospedaliera Garibaldi, UO Oncologia Medica, Catania, 95126, Italy|Università ""G. D'Annunzio"" Facoltà di Medicina e Chirurgia, Clinica Dermatologica, Chieti, 66100, Italy|Azienda Ospedaliera Umberto I° UO Servizio di Oncologia e Chemioterapia, Enna, 94100, Italy|Università di Firenze Dipartimento di Scienze Dermatologiche, Firenze, 50121, Italy|Ospedale Pierantoni, Divisione Oncologia Medica, Forli, 47100, Italy|Istituto NazionaleRicerca sul Cancro, Dipartimento di Oncologia Medica 1, Genova, 16132, Italy|Istituto Europeo di Oncologia, Divisione di Chirurgia Generale, Milano, 20141, Italy|Casa di Cura San Pio X, UO Oncologia Medica, Milano, 20159, Italy|Ospedale Civile, UO di Oncologia, Ragusa, 97100, Italy|Azienda Ospedaliera Bianchi-Melacrino-Morelli, Oncologia Medica, Reggio Calabria, 89100, Italy|Università di Roma ""Tor Vergata"" Oncologia Complementare, Dipartimento di Chirurgia, Roma, 00133, Italy|IFO Polo Oncologico Ist. Regina Elena, Divisione di Oncologia Medica A, Roma, 00144, Italy|Ospedale Sandro Pertini, Oncologia Medica, Roma, 00157, Italy|Università ""La Sapienza"" Dipartimento di Malattie Cutanee-Veneree e Chirurgia Plastica Ricostruttiva, Roma, 00161, Italy|Istituto Dermopatico dell'Immacolata, Dipartimento di Immunodermatologia, Roma, 00167, Italy|Policlinico ""Le Scotte"" Dipartimento di Medicina Clinica, Scienze Immunologiche Applicate, Divisione di Dermatologia, Siena, 53100, Italy|U.O. Complessa, Immunoterapia Oncologica, Policlinico ""Le Scotte"", Siena, 53100, Italy|Ospedale Umberto I°, Divisione di Oncologia Medica, Siracusa, 96100, Italy|Ospedale Bel Colle UO di Oncologia, Viterbo, 01100, Italy|Katedra i Klinika Onkologii i Radioterapii Akademia Medyczna, Gdansk, 80-211, Poland|Instytut Onkologii im. Marii Sklodowskiej-Curie, Oddzial w Krakowie, Klinika Chemioterapii, Krakow, 31-115, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Klinika Chemioterapii Oncologicznej, Lodz, 93-509, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Klinika Chirurgii Onkologicznej, Lublin, 20-081, Poland|Wielkopolskie Centrum Onkologii, Zaklad Immunologii Nowotworow Katedry Onkologii AM, Poznan, 61-868, Poland|Oddzial Chemioterapii, Szczecin, 71-730, Poland|Klinika Onkologii Centralnego Szpitala WAM, Warszawa, Poland|Dolnoslakie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, 53-439, Poland|Instituto Portugues de Oncologia de Francisco Gentil, Centro Regional de Oncologia de Lisboa S.A., Servicio de Medicina Oncologica 1, Pavilhao C, Lisboa, 1099-023, Portugal|Instituto Portugues de Oncologia de Francisco Gentil, Centro Regional de Oncologia do Porto S.A., Servicio de Medicina Oncologica, Piso 3, Porto, 4200, Portugal|Instituto Catalan Oncologico, Servicio de Oncologia, L'hospitalet de Llobregat, Barcelona, 08907, Spain|Hosp. Univ. de Canarias Servicio de Oncologia Medica, La Laguna, Santa Cruz de Tenerife, 38320, Spain|Hosp. Clinic i Provincial Servicio de Oncologia, Barcelona, 08036, Spain|Hosp. Universitario de Jaen Servicio de Oncologia, Jaen, 23007, Spain|Hosp. Clinico San Carlos Servicio de Oncologia, Pabellon B, Ala Sur-Sotano, Madrid, 28040, Spain|Hosp. Virgen de la Victoria de Malaga Servicio de Oncologia 1a planta Campus Universitario de Teatinos, Malaga, 29010, Spain|Hosp. Virgen del Rocio Servicio de Oncologia, Planta Baja - Centro de Diagnostico, Sevilla, 41013, Spain|Instituto Valenciano Oncologico, Valencia, 46009, Spain|Hospital General Universitario de Valencia Unidad de Oncologia Medica, Valencia, 46014, Spain|Zentrum fur Onkologie Hematologie und Transfusionsmedizin am Kantonsspital Aarau, Aarau, CH-5001, Switzerland"
NCT04904185,ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT04904185,NO,Malignant Melanoma,DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|BIOLOGICAL: Multiple Antigen Specific Endogenously derived T cells|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"National Center for Cancer Immune Therapy (CCIT-DK), Herlev, 2730, Denmark"
NCT04382664,UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma,https://clinicaltrials.gov/study/NCT04382664,NO,Malignant Melanoma,BIOLOGICAL: UV1|BIOLOGICAL: Sargramostim|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"Mayo Clinic Hospital, Phoenix, Arizona, 85016-4880, United States|Highlands Oncology Group, Fayetteville, Arkansas, 72703, United States|University of California Irvine Health, Orange, California, 92868, United States|California Cancer Associates for Research & Excellence (CCARE, San Marcos, California, 92083, United States|Ridley-Tree Cancer Center, Santa Barbara, California, 93105, United States|Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, 90404, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Holy Cross Medical Group, Fort Lauderdale, Florida, 33308, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, 33136-1002, United States|Ocala Oncology Center, Ocala, Florida, 34474, United States|Rush University Medical Center - Rush University Cancer Center, Chicago, Illinois, 60612-3841, United States|NorthShore University Research Institute, Evanston, Illinois, 60201-1718, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|Norton Cancer Institute, Louisville, Kentucky, 40241, United States|Nebraska Cancer Specialists- Midwest Cancer Center, Papillion, Nebraska, 68046-5706, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|State University of New York (SUNY) Upstate Medical University, New York, New York, 13210, United States|University of Rochester, Rochester, New York, 14642-0001, United States|NorthShore University HealthSystem, Greenville, South Carolina, 29607, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246-2092, United States|Antwerp University Hospital, Antwerp, 2650, Belgium|Cliniques Universitaires Saint-Luc, Brussel, 1200, Belgium|Leuven University Hospital, Leuven, 3000, Belgium|GZA Hospital Sint-Augustinus, Wilrijk, 2610, Belgium|Sykehuset Østfold HF, Gralum, 1714, Norway|Sørlandet Sykehus HF(SSHF), Kristiansand, 4615, Norway|Oslo University Hospital - The Norwegian Radium Hospital, Oslo, 4953, Norway|Stavanger University Hospital, Stavanger, 4068, Norway|Universitetssykehuset Nord-Norge HF, Tromsø, 9019, Norway|St. Olavs Hospital HF, Trondheim, 7030, Norway|Ålesund Hospital- Helse Sunnmore HF, Ålesund, 6026, Norway|University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Velindre NHS Trust, Cardiff, CF15 7QZ, United Kingdom|The Royal Free London NHS Foundation Trust - The Royal Free Hospital, London, NW3 2QG, United Kingdom|Royal Marsden Hospital - Institute of Cancer Research - Chelsea, London, SM2 7LN, United Kingdom|Cancer Research UK Manchester Institute, Manchester, M20 4BX, United Kingdom|Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, OX3 7LE, United Kingdom"
NCT03383237,Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma,https://clinicaltrials.gov/study/NCT03383237,NO,Malignant Melanoma,DRUG: Apatinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Henan Cancer Hospital, Zhengzhou, Henan, 450008, China"
NCT02303951,Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC,https://clinicaltrials.gov/study/NCT02303951,NO,Malignant Melanoma,DRUG: Vemurafenib|DRUG: Cobimetinib|DRUG: Atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"Department of Dermatology & Skin Cancer University Hospital La Timone, Aix-Marseille University, Marseille, 13385, France|Department of Dermatology, University Hospital of Nantes, Nantes, 44093, France|Hopital Saint-Louis Hopitaux Universitaires Saint-Louis Laboisiere Fernand-Widal, Paris, 75010, France|Department of Dermatology, Elbe Hospital, Buxtehude, 21614, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Department of Dermatology, University Hospital, Kiel, 24105, Germany|University hospital Tübingen, Tübingen, 72076, Germany"
NCT03903458,Tinostamustine and Nivolumab in Advanced Melanoma,https://clinicaltrials.gov/study/NCT03903458,NO,Malignant Melanoma,DRUG: Tinostamustine,ALL,"ADULT, OLDER_ADULT",PHASE1,"Kantonsspital Graubünden, Chur, 7000, Switzerland|Cantonal Hospital St.Gallen, St.Gallen, 9007, Switzerland"
NCT00111696,Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma,https://clinicaltrials.gov/study/NCT00111696,NO,Malignant Melanoma,BIOLOGICAL: MEDI-522,ALL,"ADULT, OLDER_ADULT",PHASE1,"University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, United States"
NCT01705392,Bevacizumab vs Dacarbazine in Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01705392,NO,Metastatic Malignant Melanoma|Unresectable Malignant Melanoma,DRUG: Bevacizumab|DRUG: Propranolol|DRUG: Enalapril|DRUG: Dacarbazine,ALL,"ADULT, OLDER_ADULT",PHASE2,"Haukeland University Hospital, Bergen, 5021, Norway"
NCT05756556,T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT05756556,NO,Melanoma|Malignant Melanoma,COMBINATION_PRODUCT: T3011 + Cobimetinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Gabrail Cancer and Research Center, Canton, Ohio, 44718, United States"
NCT04223648,Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma,https://clinicaltrials.gov/study/NCT04223648,NO,Malignant Melanoma,"DRUG: tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy",ALL,"ADULT, OLDER_ADULT",EARLY_PHASE1,
NCT04126876,A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma,https://clinicaltrials.gov/study/NCT04126876,NO,Malignant Melanoma,DRUG: Tilsotolimod|DRUG: Saline (0.9% sodium chloride),ALL,"ADULT, OLDER_ADULT",PHASE2,"VU Medical Centere, Amsterdam, 1081 HV, Netherlands"
NCT00104884,FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma,https://clinicaltrials.gov/study/NCT00104884,YES,Malignant Melanoma|Melanoma,DRUG: Depsipeptide,ALL,"ADULT, OLDER_ADULT",PHASE2,
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,https://clinicaltrials.gov/study/NCT02434354,YES,Malignant Melanoma,DRUG: pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States"
NCT02902042,Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,https://clinicaltrials.gov/study/NCT02902042,NO,Malignant Melanoma,DRUG: Encorafenib|DRUG: Binimetinib|DRUG: Pembrolizumab|DRUG: Pembrolizumab alone,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, 79106, Germany|Klinikum Augsburg Süd, Augsburg, Bavaria, 86179, Germany|Klinikum rechts der Isar, München, Bavaria, 81675, Germany|Klinikum Nürnberg Nord, Nürnberg, Bavaria, 90419, Germany|Vivantes Klinikum im Friedrichshain, Berlin Friedrichshain, Berlin, 10249, Germany|Universitätsklinikum Gießen und Marburg GmbH, Klinik für Dermatologie und Allergologie, Gießen, Hessen, 35392, Germany|Universitätsklinikum der RWTH Aachen, Aachen, Nordrhein-Westfalen, 52074, Germany|University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, 45122, Germany|HELIOS Klinikum Krefeld, Krefeld, North Rhine-Westphalia, 47805, Germany|Gesellschaft für Klinische Forschung Ludwigshafen mbH, Ludwigshafen am Rhein, Rheinland-Pfalz, 67063, Germany|Städtisches Klinikum Dessau, Dessau, Saxony-Anhalt, 06847, Germany"
NCT00350597,GM-CSF as Adjuvant Therapy of Melanoma,https://clinicaltrials.gov/study/NCT00350597,NO,Malignant Melanoma,DRUG: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF),ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,"Northern California Melanoma Center, San Francisco, California, 94109, United States"
NCT04889118,Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study,https://clinicaltrials.gov/study/NCT04889118,YES,Malignant Melanoma,BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: Placebo for lenvatinib,ALL,"ADULT, OLDER_ADULT",PHASE3,"Beijing Cancer Hospital (0601), Beijing, Beijing, 100036, China|Fujian Provincial Cancer Hospital ( Site 0612), Fuzhou, Fujian, 350014, China|Sun Yat-Sen University Cancer Center (0602), Guangzhou, Guangdong, 510000, China|Henan Cancer Hospital ( Site 0610), Zhengzhou, Henan, 450003, China|Nanjing Drum Tower Hospital (0609), Nanjing, Jiangsu, 210008, China|The First Hospital Of Jilin University (0603), Chang Chun, Jilin, 130021, China|Fudan University Shanghai Cancer Center ( Site 0607), Shanghai, Shanghai, 200032, China|Tianjin Medical University Cancer Institute & Hospital (0606), Tianjin, Tianjin, 300060, China|Yunnan Cancer Hospital (0604), Kunming, Yunnan, 430030, China|Sir Run Run Shaw Hospital (0605), Hangzhou, Zhejiang, 310018, China|Zhejiang Cancer Hospital ( Site 0608), Hangzhou, Zhejiang, 310022, China"
NCT02828202,"Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary",https://clinicaltrials.gov/study/NCT02828202,NO,Malignant Melanoma,OTHER: Biological|OTHER: Tissular|OTHER: Quality of life,ALL,"ADULT, OLDER_ADULT",,"CHU d'Amiens, Amiens, France|CH Annecy Genevois, Annecy, France|CHU de Besançon, Besançon, France|Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Avicennes, Bobigny, 93000, France|CHU de Bordeaux Hôpital Haut Levêque, Bordeaux, France|CHU de Bordeaux Hôpital Saint-André, Bordeaux, France|Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré, Boulogne-Billancourt, France|CHU de Brest, Brest, France|CHU de Caen, Caen, France|Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Créteil, 94000, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHRU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Hospices Civils de Lyon, Lyon, France|AP-HM Hopital de la Timone, Marseille, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|CHRU de Nîmes, Nîmes, France|Assistance Publique - Hôpitaux de Paris (AP-HP), Hopital Saint-Louis, centre d'oncodermatologie, Paris, France|Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bichat, Paris, France|Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Cochin, Paris, France|CHU de Rennes, Rennes, France|CLCC Eugène Marquis, Rennes, France|CHU de Toulouse, Toulouse, France"
NCT02612168,Melanoma Image Analysis Algorithm (MIAA) Validation Study,https://clinicaltrials.gov/study/NCT02612168,NO,Malignant Melanoma,DEVICE: Melanoma Image Analysis Algorithm (MIAA),ALL,"ADULT, OLDER_ADULT",NA,"Royal Devon and Exeter, Exeter, Devon, EX2 5DW, United Kingdom|Whipps Corss Hospital, Leytonstone, London, E11 1NR, United Kingdom|Royal Stoke University Hospital, Stoke, Staffordshire, ST4 6QG, United Kingdom|Russells Hall Hospital, Dudley, West Midlands, DY1 2HQ, United Kingdom|Bristol Royal Infirmary, Bristol, BS2 8AE, United Kingdom|Royal Free London NHS Foundation Trust, London, NW3 2QG, United Kingdom|Churchill Hospital, Oxford, OX3 7LE, United Kingdom"
NCT00034554,Study of gp75 Vaccine in Patients With Stage III and IV Melanoma,https://clinicaltrials.gov/study/NCT00034554,NO,Malignant Melanoma,BIOLOGICAL: gp75 DNA vaccine,ALL,"ADULT, OLDER_ADULT",PHASE1,"ImClone Investigational Site, New York, New York, 10021, United States"
NCT06221397,Clinical Validation Study of an AI-based CAD System for Early Non-Invasive Detection of Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT06221397,NO,"Melanoma|Melanoma, Skin",,ALL,"ADULT, OLDER_ADULT",,"University Hospital of Cruces, Barakaldo, Biscay, 48903, Spain"
NCT01002560,The Identification of Novel Prognostic Markers in Melanoma,https://clinicaltrials.gov/study/NCT01002560,NO,Malignant Melanoma,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, United Kingdom"
NCT03178851,Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma,https://clinicaltrials.gov/study/NCT03178851,YES,Malignant Melanoma,BIOLOGICAL: Atezolizumab|DRUG: Cobimetinib|BIOLOGICAL: Atezolizumab|BIOLOGICAL: Atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, 85258, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Baylor University Medical Center, Dallas, Texas, 75231, United States|Blacktown Hospital, Blacktown, New South Wales, 2148, Australia|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Mid North Coast Cancer Institute, Port Macquarie, New South Wales, 2444, Australia|Greenslopes Private Hospital; Clinic Pharmacy, Greenslopes, Queensland, 4120, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Alfred Hospital, Melbourne, Victoria, 3004, Australia|University Clinical Centre of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|University Clinic Ctr Sarajevo, Sarajevo, 71 000, Bosnia and Herzegovina|Instituto de Ensino e Pesquisa Clinica do Ceara, Fortaleza, CE, 60130-241, Brazil|Cenantron - Centro Avancado de Tratamento Oncologico, Belo Horizonte, MG, 30130-090, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, 20560-120, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, RS, 99010-090, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-903, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Hospital Amaral Carvalho, Jau, SP, 17210-120, Brazil|Cape Town Oncology Trials, Cape Town, 7570, South Africa|GVI Constantiaberg, Cape Town, 7800, South Africa|Johese Clinical Research, Centurion, 1692, South Africa|Cancercare, George, 6529, South Africa|Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, 2193, South Africa|Cancercare, Port Elizabeth, 6045, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, 0002, South Africa|Hospital Clinico Universitario de Santiago, Santiago de Compostela, LA Coruña, 15706, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, 31620, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, 41071, Spain|Hospital Universitari Quiron Dexeus, Barcelona, 08028, Spain|Hospital Clinic I Provincial, Barcelona, 08036, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Universitario Ramón y Cajal; Pharmacy, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Central Municipal Hospital - Uzhgorod State University, Uzhgorod, Chernihiv Governorate, 88017, Ukraine|Public Institution: City Multispecialty Clinical Hospital #4 under Dnipropetrovsk Regional Council, Dnipropetrovsk, 49102, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, 36022, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, 79031, Ukraine|Sumy Regional Clinical Onc Ctr, Sumy, 40005, Ukraine"
NCT06388252,Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma,https://clinicaltrials.gov/study/NCT06388252,NO,Cutaneous Malignant Melanoma,PROCEDURE: Electrochemotherapy with Intratumoral Cysplatin|PROCEDURE: Electrochemotherapy with Intravenous Bleomycin,ALL,"ADULT, OLDER_ADULT",NA,"Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia"
NCT03197636,Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients,https://clinicaltrials.gov/study/NCT03197636,NO,Malignant Melanoma,DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",,"AUH, Aarhus, 8000, Denmark"
NCT00299689,Phase II Trial of Ontak With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00299689,YES,Malignant Melanoma,DRUG: Denileukin diftitox,ALL,"ADULT, OLDER_ADULT",PHASE2,"James Graham Brown Cancer Center, Univ. of Louisville, Louisville, Kentucky, 40202, United States"
NCT01077050,SciBase International Melanoma Pivotal Study,https://clinicaltrials.gov/study/NCT01077050,YES,Malignant Melanoma,DEVICE: SciBase III Electrical Impedance Spectrometer,ALL,"ADULT, OLDER_ADULT",NA,"University of Arizona, Tucson, Arizona, 85719, United States|Sahlgrenska University Hospital, Gothenburg, 41345, Sweden"
NCT01288963,"IL-2 ""SELECT"" Tissue Collection Protocol in Patients With Advanced Melanoma",https://clinicaltrials.gov/study/NCT01288963,NO,Malignant Melanoma,DRUG: IL-2,ALL,"ADULT, OLDER_ADULT",,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States"
NCT01480323,A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2,https://clinicaltrials.gov/study/NCT01480323,NO,Malignant Melanoma,DRUG: Interleukin-2|DRUG: Ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"University Hospital Tübingen, Tübingen, 72076, Germany"
NCT02410863,Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma,https://clinicaltrials.gov/study/NCT02410863,NO,Malignant Melanoma,DRUG: Dabrafenib|DRUG: Trametinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"National Centre for Tumour Diseases (NCT), Heidelberg, BW, 69120, Germany|University Hospital Tübingen, Tübingen, BW, 72076, Germany|Elbe Kliniken Stade - Buxtehude GmbH, Clinic for Dermatology, Buxtehude, Lower Saxony, 21614, Germany|University Hospital Essen, Essen, NRW, 45147, Germany|University Hospital Mainz, Clinic for Dermatology, Mainz, Rhineland-Palatinate, 55131, Germany|Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden, Dresden, Saxony, 01307, Germany"
NCT00651703,Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients,https://clinicaltrials.gov/study/NCT00651703,NO,Malignant Melanoma,BIOLOGICAL: CYT004-MelQbG10 + Montanide|BIOLOGICAL: CYT004-MelQbG10 + Montanide + Imiquimod|BIOLOGICAL: CYT004-MelQbG10 + Imiquimod|BIOLOGICAL: CYT004-MelQbG10 intra nodal injection,ALL,"ADULT, OLDER_ADULT",PHASE2,"Ludwig Institute for Cancer Research; CHUV, Lausanne, VD, CH-1005, Switzerland|Dermatologische Klinik, UniversitätsSpital Zürich, Zurich, CH-8091, Switzerland"
NCT05050006,ITIL-168 in Advanced Melanoma,https://clinicaltrials.gov/study/NCT05050006,NO,Advanced Cutaneous Melanoma,BIOLOGICAL: ITIL-168,ALL,"ADULT, OLDER_ADULT",PHASE2,"University of California San Diego, Moores Cancer Center, La Jolla, California, 92093, United States|The Angeles Clinic and Research Institute, Los Angeles, California, 90025, United States|USC - Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|UCLA Health - Westwood Cancer Care, Los Angeles, California, 90095, United States|Stanford Cancer Institute, Stanford, California, 94305, United States|University of Colorado - Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Georgetown University Medical Center, Washington, District of Columbia, 20007, United States|The University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, 33136, United States|Orlando Health Cancer Institute, Orlando, Florida, 32806, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Rush University Cancer Center, Chicago, Illinois, 60612, United States|Loyola University Chicago, Maywood, Illinois, 60153, United States|University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, 55455, United States|Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, 07962, United States|Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, 44195, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, 18015, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Cambridge University Hospital NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, England, CB2 0QQ, United Kingdom"
NCT01689519,A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01689519,YES,Malignant Melanoma,DRUG: Placebo|DRUG: Vemurafenib|DRUG: Cobimetinib,ALL,"ADULT, OLDER_ADULT",PHASE3,"University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, 90025, United States|University of California Davis Health System, Sacramento, California, 95817, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, 95403, United States|University Of Colorado, Aurora, Colorado, 80045, United States|Florida Cancer Specialists - Broadway, Fort Myers, Florida, 33901, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Orlando Health Inc., Orlando, Florida, 32806, United States|Northwestern Center For Clinical Research, Chicago, Illinois, 60611, United States|Uni of Kansas Medical Center; Dept of Neurology, Kansas City, Kansas, 66160-7314, United States|U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology, Louisville, Kentucky, 40202, United States|Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, 63108, United States|Dartmouth-Hitchcock Medical Center; Department of Medicine, Lebanon, New Hampshire, 03756, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, 27103, United States|University Hospitals of Cleveland, Cleveland, Ohio, 44106, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, 18015, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 19107, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15261, United States|Rhode Island Hospital; Investigational Services, Providence, Rhode Island, 2903, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Lake Macquarie Private Hospital, Gateshead, New South Wales, 2290, Australia|Lismore Base Hospital; Cancer Care & Haematology Unit, Lismore, New South Wales, 2480, Australia|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Princess Alexandra Hospital, Woolloongabba, New South Wales, 2050, Australia|Royal Darwin Hospital, Casuarina, Northern Territory, 0811, Australia|Greenslopes Private Hospital, Greenslopes, Queensland, 4120, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Royal Adelaide Hospital; Hepatology, Adelaide, South Australia, 5000, Australia|Ashford Cancer Centre, Ashford SA, South Australia, 5035, Australia|Royal Hobart Hospital, Hobart, Tasmania, 7000, Australia|Launceston General Hospital; Gastroenterology Research, Launceston, Tasmania, 7250, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, 3199, Australia|Austin Hospital, Heidelberg, Victoria, 3084, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, 3000, Australia|The Alfred Hospital, Prahan, Victoria, 3181, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|Ordensklinikum Linz Elisabethinen, Linz, 4020, Austria|Landesklinikum St. Pölten, St. Pölten, 3100, Austria|Medizinische Universität Wien, Wien, 1090, Austria|Institut Jules Bordet; Department of Medical Oncology, Bruxelles, 1000, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, 3500, Belgium|CHU Sart-Tilman, Liège, 4000, Belgium|AZ Delta (Campus Rumbeke), Roeselare, 8800, Belgium|BC Cancer Agency Vancouver Island Cancer Centre, Victoria, British Columbia, V8R 6V5, Canada|Juravinski Cancer Clinic; Department of Oncology, Hamilton, Ontario, L8V 5C2, Canada|The Ottawa Hospital Cancer Center; General Campus, Ottawa, Ontario, K1H 1C4, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Hospital; Department of Med Oncology, Toronto, Ontario, M5G 2M9, Canada|London Health Sciences Centre · Victoria Hospital;Department of Pediatrics, London, Quebec, N6A 4G5, Canada|McGill University Health Centre/Glen Site / Royal Victoria Hospital, Montréal, Quebec, H2W 1S6, Canada|Masarykuv onkologicky ustav, Brno, 656 53, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, 500 05, Czechia|Fakultní nemocnice Olomouc, Olomouc, 775 20, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, 708 52, Czechia|Multiscan s.r.o., Pardubice, 532 03, Czechia|Nemocnice Na Bulovce, Prague, 180 01, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, 128 08, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, 100 34, Czechia|Fakultni nemocnice Motol; Neurologicka klinika, Praha, 150 06, Czechia|Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux, 33075, France|Hôpital Ambroise Paré - Boulogne-Billancourt; Respiratory, Boulogne Billancourt, 92104, France|CHU Clermont Ferrand - Hôpital d'Estaing, Clermont Ferrand cedex 1, 63003, France|CHU de Dijon - Hopital le Bocage, Dijon, 21000, France|Centre Hospitalier Universitaire de Grenoble - Albert Michallon, La Tronche, 38700, France|Hopital Claude Huriez - CHU Lille, Lille, 59037, France|Hopital de la Timone, Marseille, 13005, France|Hopital Saint Eloi, Montpellier, 34295, France|CHU NANTES - Hôtel Dieu; Pharmacy, Nantes, 44093, France|CHU Nice - Hopital de l'Archet 2, Nice, 06202, France|Centre Hospitalier Lyon Sud, Pierre Benite, 69495, France|Hopital Robert Debre; DERMATOLOGIE, Reims, 51092, France|Centre Eugene Marquis; Service d'oncologie, Rennes, 35042, France|St. Josef-Hospital; Studienambulanz, Bochum, 44791, Germany|Elbekliniken Buxtehude GmbH, Buxtehude, 21614, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, 01307, Germany|Helios Klinikum Erfurt, Erfurt, 99089, Germany|Universitätsklinikum Essen, Essen, 45147, Germany|Universitaetsklinikum Freiburg, Freiburg, 79106, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, 07548, Germany|Universitätsmedizin Göttingen, Göttingen, 37075, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitätsklinikum Heidelberg, Heidelberg, 69120, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Kiel; Klinik fuer Allgemeine Innere Medizin, Kiel, 24105, Germany|Universitaetsklinikum Koeln; Hematology/Oncology, Koeln, 50937, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, 55101, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, 68167, Germany|Fachklinik Hornheide, Muenster, 48157, Germany|Klinikum der Ludwigs-Maximilians-Universitaet Muenchen, München, 80337, Germany|Universitaetsklinikum Regensburg, Regensburg, 93053, Germany|Universitätsklinikum Tübingen, Tuebingen, 72076, Germany|Universitätsklinikum Wurzburg, Würzburg, 97080, Germany|Orszagos Onkologiai Intezet, Budapest, 1122, Hungary|Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza, Gyula, 5700, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Pecs, 7624, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, 6720, Hungary|Soroka Medical Center; Oncology Dept, Beer Sheva, 8410100, Israel|Rambam Health Care Campus, Haifa, 3109600, Israel|HADASSAH UNIVERSITY HOSPITAL, EIN KAREM; Oncology, Jerusalem, 9112000, Israel|Rabin Medical Center-Beilinson Campus;Hematology-Oncology, Petach Tikva, 4941492, Israel|Chaim Sheba Medical Center, Ramat Gan, 5265601, Israel|Tel Aviv Sourasky MC, Dana children's hospital;Oncology Division, Tel Aviv, 6423906, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, 47014, Italy|A.O.U. Policlinico di Modena, Modena, Emilia-Romagna, 40124, Italy|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, 00144, Italy|Istituto Nazionale per la Ricerca sul Cancro di Genova, Genova, Liguria, 16132, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia, 24127, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, 25100, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, 20133, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, 70126, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, 53100, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, 35128, Italy|Amsterdam UMC Location VUMC, Amsterdam, 1081 HV, Netherlands|Leids Universitair Medisch Centrum; Cardiology, Leiden, 2333 ZA, Netherlands|Maastricht University Medical Center, Maastricht, 6229 HX, Netherlands|Auckland City Hospital, Auckland, 1023, New Zealand|Waikato Hospital, Hamilton, 3248, New Zealand|Radiumhospitalet, Oslo, 0379, Norway|TSBHI Altai Territorial oncological dispensary, Barnaul, 656045, Russian Federation|FSBSI ""N. N. Blokhin Russian Cancer Research Center"", Moscow, 115478, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, 143423, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, 644013, Russian Federation|Pyatigorsky Oncologic Dispensary, Pyatigorsk, 357524, Russian Federation|Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, LA Coruña, 15706, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, 31008, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, 41071, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, 08036, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain|Länssjukhuset Ryhov, Jönköping, 551 85, Sweden|Skånes Universitetssjukhus, Lund, 221 85, Sweden|Sahlgrenska Sjukhuset, Mölnlycke, 435 33, Sweden|Akademiska Sjukhuset, Uppsala, 751 85, Sweden|Inselspital-Universitaetsspital Bern, Bern, 3010, Switzerland|Kantonsspital Graubuenden, Chur, 7000, Switzerland|Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Western General Hospital, Edinburgh, EH4 2XU, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, L7 8YA, United Kingdom|Barts and the London NHS Trust., London, EC1A 7BE, United Kingdom|St George's Hospital; Courtyard Clinic, London, SW17 0QT, United Kingdom|Royal Marsden Hospital - Fulham, London, SW3 6JJ, United Kingdom|Royal Marsden Hospital - London, London, SW3 6JJ, United Kingdom|Freeman Hospital, Newcastle upon Tyne, NE7 7DN, United Kingdom|Nottingham University Hospitals; QMC Campus, Nottingham, NG7 2UH, United Kingdom|Southampton General Hospital, Southampton, SO16 6YD, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LQ, United Kingdom|New Cross Hospital, Wolverhampton, WV10 0QP, United Kingdom"
NCT02902029,Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma,https://clinicaltrials.gov/study/NCT02902029,NO,Malignant Melanoma,DRUG: Vemurafenib|DRUG: Cobimetinib|DRUG: Atezolizumab,ALL,"ADULT, OLDER_ADULT",PHASE2,"Hôpital Ambroise-Paré, Boulogne-Billancourt, 92104, France|Hospital Claude Huriez, Lille, 59000, France|Hôpital de la Timone, Marseille, 13885, France|CHU de Nantes, Nantes, 44093, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, 69310, France|SLK-Kliniken Heilbronn GmbH, Heilbronn, Baden-Wuerttemberg, 74078, Germany|University Hospital Mannheim, Clinic for Dermatology, Mannheim, Baden-Wuerttemberg, 68167, Germany|National Centre for Tumour Diseases (NCT), Heidelberg, BW, 69120, Germany|University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, 45122, Germany|HELIOS Klinikum Erfurt, Erfurt, Thuringia, 99089, Germany|Charité-Universitätsmedizin Berlin, Berlin, 10117, Germany|Elbe Kliniken Stade - Buxtehude, Buxtehude, 21614, Germany|Universitätsklinik Dresden, Dresden, 01307, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, 66421, Germany|Universitäts-Hautklinik Kiel, Kiel, 24105, Germany|Universitätsklinikum Köln, Köln, 50937, Germany|Universitätsklinikum Leipzig, Leipzig, 04103, Germany|Gesellschaft für Klinische Forschung Ludwigshafen mbH, Ludwigshafen, 67063, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, 23538, Germany|Universitätsklinikum Mainz, Mainz, 55131, Germany|Johannes Wesling Klinikum Minden, Minden, 32429, Germany|Klinikum der Universität München, München, 80337, Germany|Universitätsklinikum Tübingen, Tübingen, 72076, Germany|Uniklinikum Würzburg, Würzburg, 97080, Germany|""LAIKO"" General Hospital of Athens, Athens, 11527, Greece|Military Medical Academy, Belgrad, 11000, Serbia"
NCT03820986,Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003),https://clinicaltrials.gov/study/NCT03820986,YES,Malignant Melanoma,BIOLOGICAL: Pembrolizumab|DRUG: Lenvatinib|DRUG: Placebo for lenvatinib,ALL,"ADULT, OLDER_ADULT",PHASE3,"The Angeles Clinic and Research Institute ( Site 0707), Los Angeles, California, 90025, United States|UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0704), San Francisco, California, 30322, United States|California Pacific Medical Center Research Institute ( Site 0705), San Francisco, California, 94115, United States|John Wayne Cancer Institute ( Site 0706), Santa Monica, California, 90404, United States|University of Colorado Cancer Center ( Site 0708), Aurora, Colorado, 80045, United States|Yale Cancer Center ( Site 0709), New Haven, Connecticut, 06510, United States|Baptist MD Anderson Cancer Center ( Site 0767), Jacksonville, Florida, 32207, United States|Mid-Florida Cancer Centers ( Site 0764), Orange City, Florida, 32763, United States|AMG Oncology ( Site 0714), Park Ridge, Illinois, 60068, United States|Illinois Cancer Care, PC ( Site 0765), Peoria, Illinois, 61615, United States|Minnesota Oncology Specialist, PA ( Site 0766), Fridley, Minnesota, 55432, United States|St. Vincent Frontier Cancer Center ( Site 0724), Billings, Montana, 59102, United States|Atlantic Health System ( Site 0768), Morristown, New Jersey, 07960, United States|Valley Hospital ( Site 0749), Paramus, New Jersey, 07652, United States|University of North Carolina - Cancer Hospital ( Site 0751), Chapel Hill, North Carolina, 27514, United States|OHSU Center for Health & Healing ( Site 0731), Portland, Oregon, 97239, United States|Inova Schar Cancer Institute ( Site 0739), Fairfax, Virginia, 22031-4867, United States|Lismore Base Hospital ( Site 0453), Lismore, Australian Capital Territory, 2480, Australia|Melanoma Institute Australia ( Site 0452), North Sydney, New South Wales, 2060, Australia|Westmead Hospital ( Site 0451), Westmead, New South Wales, 2145, Australia|Princess Alexandra Hospital ( Site 0454), Wooloongabba, Queensland, 4102, Australia|Eastern Health ( Site 0457), Box Hill, Victoria, 3128, Australia|Fiona Stanley Hospital ( Site 0456), Murdoch, Western Australia, 6150, Australia|LKH Universitatsklinikum Graz ( Site 0776), Graz, Steiermark, 8036, Austria|Medizinische Universitat Wien ( Site 0778), Wien, 1090, Austria|PERSONAL - Oncologia de Precisao e Personalizada ( Site 0399), Belo Horizonte, Minas Gerais, 30130-090, Brazil|Hospital de Caridade de Ijui ( Site 0391), Ijui, Rio Grande Do Sul, 98700-000, Brazil|Hospital Sao Vicente de Paulo ( Site 0396), Passo Fundo, Rio Grande Do Sul, 99010-080, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0397), Porto Alegre, Rio Grande Do Sul, 90610-000, Brazil|Instituto Nacional de Cancer Hospital do Cancer II ( Site 0394), Rio de Janeiro, 20220-410, Brazil|BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0661), Kelowna, British Columbia, V1Y 5L3, Canada|Lions Gate Hospital ( Site 0662), North Vancouver, British Columbia, V7L 2L7, Canada|Sunnybrook Research Institute ( Site 0654), Toronto, Ontario, M4N 3M5, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0652), Montreal, Quebec, H2W 3E4, Canada|McGill University Health Centre ( Site 0651), Montreal, Quebec, H4A 3J1, Canada|Centro Investigación del Cáncer James Lind ( Site 0425), Temuco, Araucania, 4780000, Chile|Fundacion Arturo Lopez Perez FALP ( Site 0421), Santiago, Region M. De Santiago, 7500921, Chile|Pontificia Universidad Catolica de Chile ( Site 0422), Santiago, Region M. De Santiago, 8330024, Chile|Sociedad Medica Aren y Bachero Limitada ( Site 0426), Santiago, Region M. De Santiago, 8420383, Chile|Oncocentro ( Site 0424), Vina del Mar, Valparaiso, 2520598, Chile|Beijing Cancer Hospital ( Site 0601), Beijing, Beijing, 100036, China|Fujian Provincial Cancer Hospital ( Site 0612), Fuzhou, Fujian, 350014, China|Sun Yat-Sen University Cancer Center ( Site 0602), Guangzhou, Guangdong, 510000, China|Henan Cancer Hospital ( Site 0610), Zhengzhou, Henan, 450003, China|Nanjing Drum Tower Hospital ( Site 0609), Nanjing, Jiangsu, 210008, China|The First Hospital Of Jilin University ( Site 0603), Chang Chun, Jilin, 130021, China|Fudan University Shanghai Cancer Center ( Site 0607), Shanghai, Shanghai, 200032, China|Tianjin Medical University Cancer Institute & Hospital ( Site 0606), Tianjin, Tianjin, 300060, China|Yunnan Cancer Hospital ( Site 0604), Kunming, Yunnan, 430030, China|Sir Run Run Shaw Hospital ( Site 0605), Hangzhou, Zhejiang, 310018, China|Zhejiang Cancer Hospital ( Site 0608), Hangzhou, Zhejiang, 310022, China|Hopital ARCHET 2 ( Site 0009), Nice, Alpes-Maritimes, 06200, France|Hopital La Timone ( Site 0002), Marseille, Bouches-du-Rhone, 13385, France|CHU Dijon Bourgogne ( Site 0010), Dijon, Cote-d Or, 21079, France|Institut Claudius Regaud IUCT Oncopole ( Site 0003), Toulouse, Haute-Garonne, 31059, France|Hopital Ambroise Pare Boulogne ( Site 0007), Boulogne-Billancourt, Hauts-de-Seine, 92100, France|CHRU Lille - Hopital Claude Huriez ( Site 0004), Lille, Nord, 59037, France|CHU de Rouen ( Site 0013), Rouen, Seine-Maritime, 76000, France|Centre Hospitalier Victor Dupouy ( Site 0012), Argenteuil, Val-d Oise, 95100, France|Institut Gustave Roussy ( Site 0001), Villejuif, Val-de-Marne, 94805, France|CHU de la Miletrie Poitiers ( Site 0011), Poitiers, Vienne, 86021, France|Klinik fur Dermatologie Allergologie und Venerologie ( Site 0035), Hannover, Baden-Wurttemberg, 30625, Germany|Universitaetsklinikum Erlangen ( Site 0044), Erlangen, Bayern, 91054, Germany|Universitaetsklinikum Wuerzburg-Department of Dermatology ( Site 0036), Wuerzburg, Bayern, 97080, Germany|Hautkrebszentrum Buxtehude ( Site 0037), Buxtehude, Niedersachsen, 21614, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 0041), Dresden, Sachsen, 01307, Germany|Universitaetsklinikum Leipzig ( Site 0040), Leipzig, Sachsen, 04103, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 0033), Kiel, Schleswig-Holstein, 24105, Germany|SRH Wald-Klinikum Gera GmbH ( Site 0042), Gera, Thuringen, 07548, Germany|HaEmek Medical Center ( Site 0306), Afula, 1834111, Israel|Soroka Medical Center ( Site 0303), Beer Sheva, 8457108, Israel|Rambam Medical Center ( Site 0301), Haifa, 3109601, Israel|Hadassah Ein Karem Hebrew University Medical Center ( Site 0305), Jerusalem, 9112001, Israel|Rabin Medical Center ( Site 0302), Petah Tikva, 4941492, Israel|Chaim Sheba Medical Center ( Site 0304), Ramat Gan, 5262000, Israel|Sourasky Medical Center ( Site 0307), Tel Aviv, 6423906, Israel|Shamir Medical Center-Assaf Harofeh ( Site 0308), Zerifin, 70300, Israel|ASST Papa Giovanni XXIII ( Site 0062), Bergamo, Abruzzo, 24127, Italy|Azienda Ospedaliera Universitaria Senese ( Site 0065), Siena, Toscana, 53100, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0064), Milano, 20133, Italy|Istituto Europeo di Oncologia ( Site 0067), Milano, 20141, Italy|Istituto Nazionale Tumori Fondazione Pascale ( Site 0061), Napoli, 80131, Italy|Istituto Oncologico Veneto ( Site 0063), Padova, 35128, Italy|Kyungpook National University Chilgok Hospital ( Site 0553), Daegu, Taegu-Kwangyokshi, 41404, Korea, Republic of|Seoul National University Hospital ( Site 0554), Seoul, 03080, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0552), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 0551), Seoul, 06351, Korea, Republic of|Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 0273), Bydgoszcz, Kujawsko-pomorskie, 85-796, Poland|Pratia MCM Krakow ( Site 0280), Krakow, Malopolskie, 30-510, Poland|Uniwersyteckie Centrum Kliniczne ( Site 0281), Gdansk, Pomorskie, 80-214, Poland|Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0278), Gliwice, Slaskie, 44-102, Poland|Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 0272), Poznan, Wielkopolskie, 60-780, Poland|Cancer Care Langenhoven Drive Oncology Centre ( Site 0805), Port Elizabeth, Eastern Cape, 6045, South Africa|Sandton Oncology Medical Group PTY LTD ( Site 0802), Johannesburg, Gauteng, 2196, South Africa|Cape Town Oncology Trials Pty Ltd ( Site 0803), Kraaifontein, Western Cape, 7570, South Africa|Hospital Duran i Reinals ICO de Hospitalet ( Site 0187), Hospitalet del Llobregat, Barcelona, 08908, Spain|Hospital Universitario Marques de Valdecilla ( Site 0181), Santander, Cantabria, 39008, Spain|Complejo Hospitalario Universitario A Coruna. CHUAC ( Site 0182), A Coruna, La Coruna, 15006, Spain|Hospital Universitario Insular de Gran Canaria ( Site 0189), Las Palmas de Gran Canaria, Las Palmas, 35001, Spain|Hospital Clinic i Provincial Barcelona ( Site 0190), Barcelona, 08036, Spain|Hospital General Universitario Gregorio Maranon ( Site 0191), Madrid, 28009, Spain|Hospital Universitario Ramon y Cajal ( Site 0183), Madrid, 28034, Spain|Hospital Universitario La Paz ( Site 0184), Madrid, 28046, Spain|Hospital Universitario Carlos Haya ( Site 0186), Malaga, 29010, Spain|Laenssjukhuset Ryhov ( Site 0215), Jonkoping, Jonkopings Lan, 551 85, Sweden|Centrallasarettet Vaxjo ( Site 0214), Vaxjo, Kronobergs Lan, 351 85, Sweden|Skanes Universitetssjukhus ( Site 0213), Lund, Skane Lan, 221 85, Sweden|Karolinska Universitetssjukhuset ( Site 0211), Solna, Stockholms Lan, 171 64, Sweden|Akademiska Sjukhuset ( Site 0218), Uppsala, Uppsala Lan, 751 85, Sweden|Norrlands Universitetssjukhus ( Site 0216), Umea, Vasterbottens Lan, 901 85, Sweden|Sahlgrenska Universitetssjukhuset ( Site 0212), Goteborg, Vastra Gotalands Lan, 413 45, Sweden|Universitaetsspital Basel ( Site 0094), Basel, Basel-Stadt, 4031, Switzerland|Kantonsspital Graubuenden ( Site 0091), Chur, Grisons, 7000, Switzerland|Kantonsspital Winterthur ( Site 0095), Winterthur, Zurich, 8401, Switzerland|Universitaetsspital Zuerich ( Site 0092), Zuerich-Flughafen, Zurich, 8058, Switzerland|Western General Hospital ( Site 0121), Edinburgh, Edinburgh, City Of, EH4 2XU, United Kingdom|Guys and St Thomas NHS Foundation Trust ( Site 0126), London, London, City Of, SE1 9RT, United Kingdom|Derriford Hospital ( Site 0129), Plymouth, PL6 8DH, United Kingdom|Singleton Hospital ( Site 0131), Swansea, SA2 8QA, United Kingdom"
NCT00060710,CP-461 in the Treatment of Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT00060710,NO,Malignant Melanoma,DRUG: CP-461,ALL,"ADULT, OLDER_ADULT",PHASE2,"Columbia Presbyterian Medical Center, New York, New York, 10032, United States"
NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,https://clinicaltrials.gov/study/NCT03551626,YES,Malignant Melanoma,DRUG: Dabrafenib|DRUG: Trametinib,ALL,"ADULT, OLDER_ADULT",PHASE3,"Novartis Investigative Site, Rosario, Sante Fe, S200KZE, Argentina|Novartis Investigative Site, Buenos Aires, C1125ABE, Argentina|Novartis Investigative Site, Cordoba, X5004BAL, Argentina|Novartis Investigative Site, Woolloongabba, Queensland, 4102, Australia|Novartis Investigative Site, Cairns, QLD 4870, Australia|Novartis Investigative Site, Rio de Janeiro, RJ, 20220410, Brazil|Novartis Investigative Site, Porto Alegre, RS, 90035-003, Brazil|Novartis Investigative Site, Sao Paulo, SP, 01246 000, Brazil|Novartis Investigative Site, Calgary, Alberta, T2N 4N2, Canada|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, London, Ontario, N6A 4L6, Canada|Novartis Investigative Site, Ottawa, Ontario, K1H 8L6, Canada|Novartis Investigative Site, Toronto, Ontario, M4N 3M5, Canada|Novartis Investigative Site, Toronto, Ontario, M5G 1Z6, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Quebec, G1R 2J6, Canada|Novartis Investigative Site, Brno, Czech Republic, 656 53, Czechia|Novartis Investigative Site, Prague 8, Czech Republic, 180 00, Czechia|Novartis Investigative Site, Zlin, Czech Republic, 762 75, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, 500 05, Czechia|Novartis Investigative Site, Ostrava, Poruba, 708 52, Czechia|Novartis Investigative Site, Prague, Prague 1, 11000, Czechia|Novartis Investigative Site, Olomouc, 779 00, Czechia|Novartis Investigative Site, Praha, 12808, Czechia|Novartis Investigative Site, Helsinki, 9, Finland|Novartis Investigative Site, Tampere, FIN-33521, Finland|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Pierre Benite, Cedex 02, 69495, France|Novartis Investigative Site, Limoges, Haute Vienne, 87000, France|Novartis Investigative Site, Rennes Cedex, Ille Et Vilaine, 35062, France|Novartis Investigative Site, Besancon Cedex, 25030, France|Novartis Investigative Site, Bobigny Cedex, 93009, France|Novartis Investigative Site, Bordeaux Cedex, 33075, France|Novartis Investigative Site, Boulogne Billancourt, 92104, France|Novartis Investigative Site, Clermont Ferrand, 63003, France|Novartis Investigative Site, Dijon, 21034, France|Novartis Investigative Site, Grenoble Cedex 9, 38043, France|Novartis Investigative Site, Lille Cedex, 59037, France|Novartis Investigative Site, Lorient, 56322, France|Novartis Investigative Site, Marseille Cedex 05, 13885, France|Novartis Investigative Site, Montpellier, 34295, France|Novartis Investigative Site, Nice, 06202, France|Novartis Investigative Site, Paris 10, 75475, France|Novartis Investigative Site, Poitiers, 86021, France|Novartis Investigative Site, Reims, 51092, France|Novartis Investigative Site, Toulouse, 31059, France|Novartis Investigative Site, Villejuif, 94800, France|Novartis Investigative Site, Athens, 115 27, Greece|Novartis Investigative Site, Athens, 18547, Greece|Novartis Investigative Site, Athens, GR 115 22, Greece|Novartis Investigative Site, Thessaloniki, 54622, Greece|Novartis Investigative Site, Budapest, H 1122, Hungary|Novartis Investigative Site, Pecs, 7623, Hungary|Novartis Investigative Site, Szeged, H 6725, Hungary|Novartis Investigative Site, Jerusalem, 9112001, Israel|Novartis Investigative Site, Ramat Gan, 52621, Israel|Novartis Investigative Site, Bergamo, BG, 24127, Italy|Novartis Investigative Site, Meldola, FC, 47014, Italy|Novartis Investigative Site, Antella - Bagno A Ripoli, FI, 50011, Italy|Novartis Investigative Site, Genova, GE, 16132, Italy|Novartis Investigative Site, Milano, MI, 20133, Italy|Novartis Investigative Site, Milano, MI, 20141, Italy|Novartis Investigative Site, Modena, MO, 41124, Italy|Novartis Investigative Site, Palermo, PA, 90127, Italy|Novartis Investigative Site, Padova, PD, 35100, Italy|Novartis Investigative Site, Roma, RM, 00128, Italy|Novartis Investigative Site, Roma, RM, 00167, Italy|Novartis Investigative Site, Torino, TO, 10126, Italy|Novartis Investigative Site, Udine, UD, 33100, Italy|Novartis Investigative Site, Napoli, 80131, Italy|Novartis Investigative Site, Sapporo, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Chuo ku, Tokyo, 104 0045, Japan|Novartis Investigative Site, Riga, LV 1079, Latvia|Novartis Investigative Site, Vilnius, LT-08660, Lithuania|Novartis Investigative Site, Alesund, NO-6026, Norway|Novartis Investigative Site, Oslo, 0379, Norway|Novartis Investigative Site, Gdansk, 80 952, Poland|Novartis Investigative Site, Warszawa, 02 781, Poland|Novartis Investigative Site, Wroclaw, 53 413, Poland|Novartis Investigative Site, Porto, 4200-072, Portugal|Novartis Investigative Site, Moscow Region Istra Village, 143423, Russian Federation|Novartis Investigative Site, Moscow, 115478, Russian Federation|Novartis Investigative Site, Omsk, 644013, Russian Federation|Novartis Investigative Site, St Petersburg, 197758, Russian Federation|Novartis Investigative Site, Bratislava, 812 50, Slovakia|Novartis Investigative Site, Kosice, 04191, Slovakia|Novartis Investigative Site, Ljubljana, 1000, Slovenia|Novartis Investigative Site, Goteborg, SE-413 45, Sweden|Novartis Investigative Site, Orebro, 701 85, Sweden|Novartis Investigative Site, Stockholm, SE 171 76, Sweden|Novartis Investigative Site, Umea, SE 901 85, Sweden|Novartis Investigative Site, Izmir, 35040, Turkey|Novartis Investigative Site, Bristol, Avon, BS2 8ED, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, HA6 2RN, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, S10 2JF, United Kingdom|Novartis Investigative Site, Cambridge, CB2 2QQ, United Kingdom|Novartis Investigative Site, Leeds, LS9 7TF, United Kingdom|Novartis Investigative Site, Manchester, M20 4BX, United Kingdom|Novartis Investigative Site, Southampton, SO16 6YD, United Kingdom"
NCT03084640,Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma,https://clinicaltrials.gov/study/NCT03084640,NO,Malignant Melanoma,DRUG: CMP-001|DRUG: Pembrolizumab|DRUG: CMP-001,ALL,"ADULT, OLDER_ADULT",PHASE1,"University of California, Los Angeles, Los Angeles, California, 90095, United States|University of Colorado, Aurora, Colorado, 80045, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, 52242, United States|University of Pittsburgh Medical Center - Cancer Center, Pittsburgh, Pennsylvania, 15232, United States"
NCT00306566,Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients,https://clinicaltrials.gov/study/NCT00306566,NO,Malignant Melanoma,BIOLOGICAL: CYT004-MelQbG10,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Centre Pluridisciplinaire d'Oncologie & LICR, CHUV, Lausanne, Vaude, 1011, Switzerland"
NCT00135408,A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide,https://clinicaltrials.gov/study/NCT00135408,NO,Malignant Melanoma,DRUG: Ipilimumab+ Placebo|DRUG: Ipilimumab+ Budesonide,ALL,"ADULT, OLDER_ADULT",PHASE2,"Los Angeles, California, United States|San Francisco, California, United States|Charlotte, North Carolina, United States|Seattle, Washington, United States|Local Institution, Kitchener, Canada|Local Institution, Moncton, Canada|Local Institution, Tel Aviv, Israel|Local Institution, Forli, Italy|Local Institution, Lima, Peru|Local Institution, Hull, United Kingdom"
NCT02938728,Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma,https://clinicaltrials.gov/study/NCT02938728,NO,Malignant Melanoma,OTHER: Biopsies,ALL,"ADULT, OLDER_ADULT",,
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT02050321,YES,Malignant Melanoma,DRUG: Acitretin|DRUG: Vemurafenib,ALL,"ADULT, OLDER_ADULT",PHASE2,"University of Arizona Cancer Center, Tucson, Arizona, 85724, United States"
NCT00715793,Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00715793,YES,Malignant Melanoma,DRUG: Decitabine|DRUG: Temozolomide|PROCEDURE: biopsy,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"UPMC Cancer Centers, Pittsburgh, Pennsylvania, 15232, United States"
NCT00204594,Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28,https://clinicaltrials.gov/study/NCT00204594,NO,Malignant Melanoma,DRUG: rM28|DRUG: autologous PBMCs,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"University of Tuebingen, Department of dermatology, Tuebingen, 72076, Germany"
NCT00086489,"CP-675,206 In Patients With Advanced Melanoma",https://clinicaltrials.gov/study/NCT00086489,NO,Malignant Melanoma,"DRUG: CP-675,206|DRUG: CP-675,206",ALL,"ADULT, OLDER_ADULT",PHASE2,"Research Site, Los Angeles, California, 90095, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Chicago, Illinois, 60637-1460, United States|Research Site, Ann Arbor, Michigan, 48109-0008, United States|Research Site, Ann Arbor, Michigan, 48109-0843, United States|Research Site, Pittsburgh, Pennsylvania, 15232-1305, United States|Research Site, Pittsburgh, Pennsylvania, 15232, United States|Research Site, Nashville, Tennessee, 37232, United States|Research Site, Houston, Texas, 77030, United States"
NCT02935790,Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,https://clinicaltrials.gov/study/NCT02935790,NO,Malignant Melanoma,DRUG: ACY-241|DRUG: nivolumab|DRUG: ipilimumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"NYU Langone Medical Center, New York, New York, 10016, United States"
NCT01748448,Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome,https://clinicaltrials.gov/study/NCT01748448,NO,Cutaneous Malignant Melanoma,DRUG: Vitamin D|DRUG: arachides oleum raffinatum,ALL,"ADULT, OLDER_ADULT",PHASE3,"Universitair Ziekenhuis Antwerpen, Dermatology, Edegem, 2650, Belgium|UZLeuven Gasthuisberg, Leuven, 3000, Belgium|Chef de Service du Service Universitaire de Dermatologie, Liège, 4000, Belgium|Dep. of Dermatology, Medical and Health Science Center University of Debrecen, Debrecen, 4032, Hungary"
NCT01307397,A Study of Vemurafenib in Participants With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01307397,YES,Malignant Melanoma,DRUG: Vemurafenib,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,"University ""Mother Theresa"" Hospital Center; Oncology Department, Tirana, 1000, Albania|Hospital Britanico; Oncologia, Buenos Aires, C1280AEB, Argentina|Fundación CIDEA, Buenos Aires, C1425DTG, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, C1426ANZ, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, 2060, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, 2298, Australia|Westmead Hospital, Westmead, New South Wales, 2145, Australia|Border Medical Oncology, Wodonga, New South Wales, 3690, Australia|Greenslopes Private Hospital; Gallipoli Research Centre, Greenslopes, Queensland, 4120, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, 4812, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, 5000, Australia|Geelong Hospital; Geelong Cardiology Practice, Geelong, Victoria, 3220, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, 3000, Australia|Alfred Hospital, Melbourne, Victoria, 3004, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin, Feldkirch, 6807, Austria|LKH Graz; Abteilung für allgemeine Dermatologie, Graz, 8036, Austria|LKH Innsbruck; Universitätsklinik für Dermatologie, Innsbruck, 6020, Austria|Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie, Linz, 4020, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, 5020, Austria|LKH Salzburg; Universitätsklinik für Dermatologie, Salzburg, 5020, Austria|Landesklinikum St. Pölten, St. Pölten, 3100, Austria|Medizinische Universität Wien; Univ.Klinik für Dermatologie, Wien, 1090, Austria|UZ Brussel, Brussel, 1090, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, 71000, Bosnia and Herzegovina|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, 20230-130, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-003, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, 01509-010, Brazil|Hospital Sao Jose, São Paulo, SP, CEP 01321-001, Brazil|District Oncology Dispensary; Department for Oncology and Dermatology, Plovdiv, 4000, Bulgaria|National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic, Sofia, 1756, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, T6G 1Z2, Canada|Lion'S Gate Hospital, North Vancouver, British Columbia, V7L 2L7, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|St. Boniface General Hospital; Medicine, Winnipeg, Manitoba, R2H 2A6, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, B3H 2Y9, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Centre, London, Ontario, N6A 4L6, Canada|The Ottawa Hospital; Division of Infectious Diseases, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, M5G 2M9, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, H3T 1E2, Canada|Chuq - Hopital Hotel Dieu de Quebec; Oncology, Quebec City, Quebec, G1R 2J6, Canada|Centro Javeriano de Oncología, Bogota, Colombia|Fundacion Santa Fe de Bogotá, Bogota, Colombia|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Clinical Hospital Sisters of Mercy, Zagreb, 10000, Croatia|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, 656 53, Czechia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Faculty Hospital; Dialysis Unit, Ostrava, 708 52, Czechia|1 Lekarska Fakulta Uni Karlovy; 3 Interni Klinika, Labor. Pro Endokrinologii A Metabolismus, Praha, 128 00, Czechia|Faculty Hospital Kralovske Vinohrady; Oncology, Praha, Czechia|Aarhus Universitetshospital; Kræftafdelingen, Aarhus C, 8000, Denmark|Herlev Hospital; Onkologisk afdeling, Herlev, 2730, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, 5000, Denmark|Hospital Regional Vicente Corral Moscoso, Servicio de Oncología, Cuenca, Ecuador|Hospital Abel Gilbert Ponton; Oncology, Guayaquil, EC090104, Ecuador|Hospital Solca Portoviejo; Oncologia, Portoviejo, EC130104, Ecuador|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, 11312, Estonia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, 13419, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, 50406, Estonia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, 00029, Finland|Tampere University Hospital; Dept of Oncology, Tampere, 33520, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, 20520, Finland|Uniklinik RWTH Aachen; Klinik für Dermatologie und Allergologie - Hautklinik, Aachen, 52074, Germany|Klinikum Augsburg Süd; Klinik für Dermatologie und Allergologie, Augsburg, 86179, Germany|CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.Hämatologie u.Onkologie, Berlin, 12200, Germany|St. Josef-Hospital Klinik f. Dermatologie u. Allergologie, Bochum, 44791, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, 21614, Germany|DRK-Krankenhaus; Hautklinik, Chemnitz, 09117, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, 01307, Germany|Universitätsklinikum Düsseldorf; Hautklinik, Düsseldorf, 40225, Germany|HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie, Erfurt, 99089, Germany|Universitätsklinikum Erlangen; Hautklinik, Erlangen, 91054, Germany|Universitätsklinikum Essen, Essen, 45122, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik fuer Allgemein- und Viszeralchirurgie, Frankfurt, 60596, Germany|Uniklinikum Freiburg Dermatol, Freiburg, 79104, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, 07548, Germany|Universitätsmedizin Göttingen Georg-August-Universität Zentrum Dermatologie, Göttingen, 37075, Germany|Universitätsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie, Hamburg, 20246, Germany|Medizinische Hochschule; Hautklinik Linden, Hannover, 30449, Germany|Uni-Hautklinik, Heidelberg, 69115, Germany|Klinikum am Gesundbrunnen; Tumorzentrum, Heilbronn, 74078, Germany|Universitätsklinikum Jena; Klinik für Hautkrankheiten, Jena, 07743, Germany|Klinikum Kassel; Hautklinik, Kassel, 34125, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, 24105, Germany|Klinik der Uni zu Köln; Klinik & Poliklinik fuer Dermatologie & Venerologie, Köln, 50937, Germany|Universitätsklinikum Leipzig Klinik f.Dermatologie Venerologie u.Allergologie, Leipzig, 04103, Germany|Klinikum d.Stadt Ludwigshafen Hautklinik, Ludwigshafen, 67063, Germany|Universitätsklinikum Schleswig-Holstein; Campus Lübeck, Lübeck, 23538, Germany|Universitätsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie, Magdeburg, 39120, Germany|Johannes Gutenberg Unis-Klinik; Dept For Dermatology, Mainz, 55131, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, 68167, Germany|Universitätsklinikum Marburg Klinik f. Dermatologie, Marburg, 35043, Germany|Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik, Minden, 32429, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, 80337, Germany|Staedtisches Krankenhaus Muenchen-Schwabing, Haematologie & Onkolgie, München, 80804, Germany|Universitätsklinikum Münster, Münster, 48149, Germany|Fachklinik Hornheide; Internistische Onkologie, Münster, 48157, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, 90419, Germany|Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie, Quedlinburg, 06484, Germany|KLINIKUM VEST GmbH Knappschaftskrankenhaus Abt.Haut- Allergie- Venen- und Umwelterkrankungen, Recklinghausen, 45657, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, 93053, Germany|Universitaets-Hautklinik Tuebingen, Tübingen, 72076, Germany|Wilhelm Fresenius Klinik; Klinik f. Dermatologie u. Allergologie, Wiesbaden, 65191, Germany|HELIOS Klinikum Barmen Zentrum Dermatologie Allergologie und Umweltmedizin, Wuppertal, 42283, Germany|Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, 97080, Germany|Laiko General Hospital; 1St Pathological Clinic, Athens, 115 27, Greece|Hospital Hygeia; 1St Oncology Dept., Athens, 15123, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, 711 10, Greece|Metropolitan Hospital; Dept. of Oncology, Piraeus, 185 47, Greece|Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika, Budapest, 1085, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, 1122, Hungary|Debreceni Egyetem OEC; Borgyogyaszati Klinika, Debrecen, 4012, Hungary|Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika, Pecs, 7632, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, 6720, Hungary|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, 110085, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, 400012, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, 422004, India|Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, 500034, India|Chhatrapati Shahuji Maharaj Medical University; Department of Oncology, Lucknow, 226003, India|Regional Cancer Centre; Dept of Oncology, Trivandrum, 695 011, India|Christian Med Clg & Hspt, Vellore, 632004, India|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, 4, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, 7, Ireland|Mater Private Hospital, Dublin, 7, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Soroka Medical Center; Oncology Dept, Beer Sheva, 8410101, Israel|Ranbam Health Care Campus; Oncology - Hafia, Hafia, 3109601, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, 91120-01, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, 5262100, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, 47014, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, 41100, Italy|AO Santa Maria Nuova; U.O. Day Hospital di Oncologi, Reggio Emilia, Emilia-Romagna, 42100, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, 33100, Italy|Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica, Roma, Lazio, 00167, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, 00168, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, 24128, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, 25123, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, 20132, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, 20141, Italy|Policlinico Le Molinette; Clinica Dermatologica, Torino, Piemonte, 10126, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, 70126, Italy|Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1, Palermo, Sicilia, 90127, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, 50139, Italy|Azienda Ospedaliera S. Chiara; Dip di Onc,Trapianti e delle Nuove Tecnologie in Medicina, Pisa, Toscana, 50126, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, 53100, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, 05100, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, 35128, Italy|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Seoul St Mary's Hospital, Seoul, 06591, Korea, Republic of|Seoul National University Hosp; Dept Internal Med Hem Onc, Seoul, 110-744, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, 120-752, Korea, Republic of|Asan Medical Center., Seoul, 138-736, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, 5417, Latvia|Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs, Riga, LV 1079, Latvia|Klaipeda University Hospital, Klaipeda, 92288, Lithuania|Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center, Vilnius, 08661, Lithuania|University Clinic for Radiotherapy and Oncology Skopje; Department of skin malignancies, Skopje, 1000, Macedonia, The Former Yugoslav Republic of|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, 37000, Mexico|Inst. Nacional de Cancerologia; Investigacion Clinica, Mexico City, 14000, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, 06726, Mexico|Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde, Amsterdam, 1066 CX, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, 1081 HV, Netherlands|Tergooiziekenhuizen, Blaricum, 1261 AN, Netherlands|Amphia Ziekenhuis, Breda, 4818 CK, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, 9713 GZ, Netherlands|Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, 2333 ZA, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, 6229 HX, Netherlands|UMC St Radboud; Interne Oncologie; Medical Oncology Department, Nijmegen, 6500 HB, Netherlands|Erasmus MC, Rotterdam, 3000 CA, Netherlands|Universitair Medisch Centrum Utrecht; Inwendige Geneeskunde Afd., Utrecht, 3584 CX, Netherlands|Haukeland Universitetshospital; Onkologisk Avd., Bergen, 5021, Norway|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, 0379, Norway|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, 04001, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, 34, Peru|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Krakow, 31-531, Poland|ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii;Wojska Polskiego 37, Olsztyn, 10-228, Poland|NZOZ Med.-Polonia sp. z o.o., Poznań, 60-693, Poland|Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie, Warszawa, 02-781, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucuresti, 022328, Romania|Medisprof SRL, Cluj-Napoca, 400058, Romania|S.C. Life Search S.R.L; Medical Oncology Clinic, Timisoara, 300167, Romania|FSBI ""Scientific Research Institute of Oncology named after N.N.Petrov"" Ministry of Health of RF, St Petersburg, Leningrad, 197758, Russian Federation|Regional Clinical Oncology Dispensary, Krasnodar, 350040, Russian Federation|Russian Cancer Research Center, Moscow, 115478, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, 143423, Russian Federation|St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint-Petersburg, 197022, Russian Federation|Stavropol Clinical Oncology Dispansary, Stavropol, ND, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, 450054, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, 11000, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, 11080, Serbia|Onkologicky ustav sv. Alzbety; Oddelenie ambulantnej chemoterapie, Bratislava, 812 50, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie E, Bratislava, 833 10, Slovakia|POKO Poprad; Department of Oncology, Poprad, 058 01, Slovakia|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Universitas Annex, University of the Free State; Clinical Oncology, Bloemfontein, 9300, South Africa|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Cancercare, Cape Town, 7700, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, 2196, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, 0002, South Africa|Sandton Oncology Centre, Sandton, 2196, South Africa|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, 33011, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, 39008, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, 07014, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, 35016, Spain|Hospital Universitario de Santa Lucía; Servicio de Oncología Médica, Cartagena (Murcia), Murcia, 30202, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, 31008, Spain|Hospital Xeral Cíes; Servicio de Oncologia, Vigo, Pontevedra, 36312, Spain|Hospital Universitario de Canarias (HUC), La Laguna (Tenerife), Tenerife, 38320, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, 48903, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, 08035, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, 08036, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, 08916, Spain|Hospital Reina Sofia, Cordoba, 14004, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, 18014, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, 15006, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, 24071, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, 29010, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, 37007, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, 41009, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, 41014, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, SE-41 343, Sweden|Skånes Onkologiska Klinik, Universitetssjukhuset, Lund, 22185, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, 171 76, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 75185, Sweden|Universitaetsspital Basel; Onkologie, Basel, 4031, Switzerland|Inselspital Bern; Medizinische Onkologie, Bern, 3010, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, 7000, Switzerland|CHUV; Departement d'Oncologie, Lausanne, 1011, Switzerland|Kantonsspital St. Gallen; Onkologie/Hämatologie, St. Gallen, 9007, Switzerland|Universitätsspital Zürich; Dermatologische Klinik, Zürich, 8091, Switzerland|Adana Baskent University Hospital; Medical Oncology, Adana, 01120, Turkey|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, 01330, Turkey|Ankara Uni , Ibn-I Sina Hospital; Oncology Dept, Ankara, 06230, Turkey|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, 06500, Turkey|Akdeniz University School of Medicine; General Surgery, Antalya, 07000, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, İZMİR, 35100, Turkey|Gaziantep University Medical Faculty, Medical Oncology Department, Gaziantep, 27310, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, 34000, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, 34300, Turkey|American Hospital, Medical Oncology Department, Istanbul, 34365, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, 35340, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, ANKARA, 06100, Turkey|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, GU2 7XX, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Royal Marsden Hospital, London, SW3 6JJ, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, M20 4QL, United Kingdom|Northern Centre for Cancer Care Freeman Hospital; Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, NE7 7DN, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, HA6 2RN, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, NG5 1PB, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, OX3 7LJ, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, SO16 6YD, United Kingdom|Singleton Hospital; Oncology, Swansea, SA2 8QA, United Kingdom"
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,https://clinicaltrials.gov/study/NCT02523313,NO,Malignant Melanoma,DRUG: Nivolumab + Placebo|DRUG: Nivolumab + Ipilimumab|DRUG: Double Placebo Control,ALL,"ADULT, OLDER_ADULT",PHASE2,"Charité Berlin, Berlin, 10117, Germany|Elbe Klinikum Buxtehude, Buxtehude, 21614, Germany|Universitätsklinikum Dresden, Dresden, 01307, Germany|HELIOS Klinikum Erfurt, Erfurt, 99089, Germany|Studienzentrum Hautklinik Universitätsklinikum Essen (AöR) Klinik für Dermatologie, Essen, 45147, Germany|SRH Wald-Klinikum Gera GmbH, Gera, 07548, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitätrsklinikum Heidelberg Dermatologie / NCT, Heidelberg, 69120, Germany|SLK Kliniken Heilbronn GmbH, Heilbronn, 74078, Germany|Universitäts-Hautklinik Kiel Klinik f. Dermatologie, Venerologie u. Allergologie, Kiel, 24105, Germany|Universitätsklinikum Leipzig Klinik u. Poliklinik f. Dermatologie, Venerologie u. Allergologie, Leipzig, 04103, Germany|Klinikum der Stadt Ludwigshafen, Ludwigshafen, 67063, Germany|UKSH Campus Lübeck, Lübeck, 23538, Germany|Universitätsklinikum Mainz Hautklinik und Polklinik, Mainz, 55131, Germany|Klinik für Dermatologie, Venerologie und Allergologie UMM - Universitätsmedizin Mannheim, Mannheim, 68167, Germany|Johannes Wesling Klinikum Minden Hautklinik, Minden, 32429, Germany|Universitätsklinikum München (LMU), München, 80337, Germany|Fachklinik Hornheide, Münster, 48157, Germany|Universitätsklinikum Regensburg, Regensburg, 93053, Germany|Universitätshautklinik Tübingen, Tübingen, 72076, Germany"
NCT00483301,"A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma",https://clinicaltrials.gov/study/NCT00483301,NO,Malignant Melanoma,DRUG: Sorafenib (BAY 43-9006)|DRUG: ABI-007(Abraxane),ALL,"ADULT, OLDER_ADULT",PHASE2,"Dr. Steven O'Day, Los Angeles, California, 90025, United States|Mt. Sinai Medical Center, Miami Beach, Florida, 33140, United States"
NCT01656642,A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01656642,NO,Malignant Melanoma,DRUG: Atezolizumab|DRUG: Cobimetinib|DRUG: Vemurafenib,ALL,"ADULT, OLDER_ADULT",PHASE1,"UCLA, Los Angeles, California, 90024, United States|The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, 90025, United States|University of Colorado Health Science Center; Biomedical Research Bldg. Room 511, Aurora, Colorado, 80045, United States|Florida Cancer Specialists - Sarasota, Sarasota, Florida, 34232, United States|Massachusetts General Hospital., Boston, Massachusetts, 02114, United States|Dana Farber Can Ins, Boston, Massachusetts, 02215, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT01704287,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002),https://clinicaltrials.gov/study/NCT01704287,YES,Malignant Melanoma,BIOLOGICAL: Pembrolizumab|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Dacarbazine|DRUG: Temozolomide,ALL,"ADULT, OLDER_ADULT",PHASE2,
NCT01248936,A Study of RO5185426 in Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01248936,YES,Malignant Melanoma,DRUG: RO5185426,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,"Tucson, Arizona, 85724-5078, United States|Los Angeles, California, 90095, United States|San Francisco, California, 94115, United States|San Francisco, California, 94117, United States|Santa Monica, California, 90025, United States|Aurora, Colorado, 80045, United States|New Haven, Connecticut, 06520-8063, United States|Palm Harbor, Florida, 34684, United States|Tampa, Florida, 33612-9497, United States|Atlanta, Georgia, 30322, United States|Park Ridge, Illinois, 60068, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48201, United States|St. Louis, Missouri, 63110, United States|New York, New York, 10016, United States|New York, New York, 10029, United States|New York, New York, 10032, United States|New York, New York, 10065, United States|Cincinnati, Ohio, 45242, United States|Oklahoma City, Oklahoma, 73104, United States|Portland, Oregon, 97225, United States|Philadelphia, Pennsylvania, 19104, United States|Columbia, South Carolina, 29210, United States|Nashville, Tennessee, 37203, United States|Dallas, Texas, 75246, United States|Richmond, Virginia, 23230, United States|Seattle, Washington, 98195, United States"
NCT02186249,Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma,https://clinicaltrials.gov/study/NCT02186249,NO,Malignant Melanoma,DRUG: Nivolumab|DRUG: Ipilimumab,ALL,"ADULT, OLDER_ADULT",,"Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|Mayo Clinic Arizona, Phoenix, Arizona, 85054, United States|6501 Truxtun Avenue, Bakersfield, California, 93309, United States|UC San Diego Moores Cancer Center, La Jolla, California, 92093, United States|100 UCLA Medical Plaza, Los Angeles, California, 90095, United States|514 North Prospect Ave, Redondo Beach, California, 90277, United States|California Pacific Medical Center Research Institute, San Francisco, California, 94115, United States|University of California San Francisco, San Francisco, California, 94115, United States|Angeles Clinic and Research Institute, Santa Monica, California, 90404, United States|1325 East Church Street, Santa Monica, California, 93454, United States|University of Colorado Hospital, Aurora, Colorado, 80045, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, 80120, United States|Smilow Cancer Hospital at Yale University Cancer Center, New Haven, Connecticut, 06519, United States|Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, 20007, United States|Memorial Regional Hospital, Hollywood, Florida, 33021, United States|4500 San Pablo Road South, Jacksonville, Florida, 32224, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|UF Health Cancer Center at Orlando Health, Longwood, Florida, 32750, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, 33612, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|600 Celebrate Life Parkway, Newnan, Georgia, 30265, United States|Evanston Premier Healthcare Research LLC, Evanston, Illinois, 60201, United States|Oncology Specialists, SC, Niles, Illinois, 60714, United States|Local Institution, Louisville, Kentucky, 40202, United States|Medstar Health Research Institute, Baltimore, Maryland, 21204, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, 49503, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|Atlantic Health System, Morristown, New Jersey, 07960-1089, United States|NYU Langone Medical Center, New York, New York, 10016, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10017, United States|Carolinas Healthcare System, Charlotte, North Carolina, 28204, United States|Tulsa Cancer Institute PLLC, Tulsa, Oklahoma, 74146, United States|Northwest Cancer Specialists PC, Portland, Oregon, 97213, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, 18103, United States|St Luke's Hospital, Bethlehem, Pennsylvania, 18015, United States|Greenville Health System, Easley, South Carolina, 29640, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Texas Oncology, Austin, Texas, 78731, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Texas Oncology, Midland, Texas, 79701, United States|Texas Oncology, Paris, Texas, 75460, United States|Virginia Cancer Institute, Richmond, Virginia, 23230, United States|Oncology and Hematology Associates of Southwest Virginia, Inc, Roanoke, Virginia, 24014, United States|Shenandoah Oncology Association, Winchester, Virginia, 22601, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|University of Wisconsin, Madison, Wisconsin, 53792, United States|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, V5Z 4E6, Canada|Grand River Hospital, Kitchener, Ontario, N2G 1G3, Canada|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, L1G 2B9, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|McGill University Health Center, Montreal, Quebec, H4A 3J1, Canada|Chuq Centre Hospitalier Universitaire de Quebec, Quebec, G1R 2J6, Canada"
NCT00370136,Sentinel Node With Ultrasound Contrast in Melanoma,https://clinicaltrials.gov/study/NCT00370136,NO,Malignant Melanoma,DRUG: ultrasound contrast,ALL,"ADULT, OLDER_ADULT",NA,"Copenhagen univercity hospital, Department of Radiology, section of ultrasound, Copenhagen, 2100, Denmark"
NCT01522664,A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma,https://clinicaltrials.gov/study/NCT01522664,NO,Malignant Melanoma,DRUG: DEDN6526A,ALL,"ADULT, OLDER_ADULT",PHASE1,"Los Angeles, California, 90025, United States|Sarasota, Florida, 34232, United States|Detroit, Michigan, 48201, United States|Nashville, Tennessee, 37203, United States|Camperdown, New South Wales, 2050, Australia|East Melbourne, Victoria, 3002, Australia"
NCT01511913,"A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma",https://clinicaltrials.gov/study/NCT01511913,NO,Advanced Cutaneous Melanoma,,ALL,"ADULT, OLDER_ADULT",,"Local Institution, Gilbert, Arizona, 85234, United States|Local Institution, Hot Springs, Arkansas, 71913, United States|Local Institution, Encinitas, California, 92024, United States|Local Institution, La Jolla, California, 92093, United States|Local Institution, Long Beach, California, 90813, United States|Local Institution, Los Angeles, California, 90025, United States|Local Institution, Denver, Colorado, 80218, United States|Local Institution, Washington, District of Columbia, 20010, United States|Local Institution, Lakeland, Florida, 33085, United States|Local Institution, Miami Beach, Florida, 33140, United States|Local Institution, Orange Park, Florida, 32073, United States|Local Institution, Chicago, Illinois, 60612, United States|Local Institution, Niles, Illinois, 60714, United States|Local Institution, Detroit, Michigan, 48201, United States|Local Institution, Hattiesburg, Mississippi, 39401, United States|Local Institution, Lincoln, Nebraska, 18015, United States|Local Institution, Morristown, New Jersey, 07960, United States|Local Institution, Canton, Ohio, 44178, United States|Mid Ohio Onc/Hem, Inc, Columbus, Ohio, 43206, United States|Local Institution, Columbus, Ohio, 43219, United States|Local Institution, Middletown, Ohio, 45042, United States|Local Institution, Portland, Oregon, 97213, United States|Local Institution, Knoxville, Tennessee, 37920, United States|Local Institution, Everett, Washington, 98201, United States|Local Institution, Caba, 1426, Argentina|Local Institution, Caba, C1417DNT, Argentina|Local Institution, Caba, C1426ANZ, Argentina|Local Institution, Cordoba, X5006HBF, Argentina|Local Institution, Rosario- Santa Fe, S2000KZE, Argentina|Local Institution, Tucuman, T4000GTB, Argentina|Local Institution, Canberra, Australian Capital Territory, 02605, Australia|Local Institution, Corrimal, New South Wales, 02518, Australia|Local Institution, Lismore, New South Wales, 02480, Australia|Local Institution, Port Macquarie, New South Wales, 02444, Australia|Local Institution, Tamworth, New South Wales, 02340, Australia|Local Institution, Tweeds Head, New South Wales, 02485, Australia|Local Institution, Wagga Wagga, New South Wales, 2650, Australia|Local Institution, Waratah, New South Wales, 02298, Australia|Local Institution, Cairns, Queensland, 4870, Australia|Local Institution, Douglas, Queensland, 04810, Australia|Local Institution, Greenslopes, Queensland, 4120, Australia|Local Institution, Adelaide, South Australia, 05000, Australia|Local Institution, Bedford Park, South Australia, 05042, Australia|Local Institution, Kurralta Park, South Australia, 5037, Australia|Local Institution, Frankston, Victoria, 03199, Australia|Local Institution, Malvern, Victoria, 03144, Australia|Local Institution, Feldkirch, 6800, Austria|Local Institution, Graz, A-8036, Austria|Local Institution, Linz, A-4020, Austria|Local Institution, Salzburg, A-5020, Austria|Local Institution, St Poelten, A-3100, Austria|Local Institution, Vienna, A-1090, Austria|Local Institution, Brasschaat, 2930, Belgium|Local Institution, Brussels, 1200, Belgium|Local Institution, Edegem, 2650, Belgium|Local Institution, Haint Saint Paul, 7100, Belgium|Local Institution, Hasselt, 3500, Belgium|Local Institution, Kortrijk, 8500, Belgium|Local Institution, Leuven, 3000, Belgium|Local Institution, Moncton, New Brunswick, E1C 6Z8, Canada|Local Institution, London, Ontario, N6C 6B5, Canada|Local Institution, Mississauga, Ontario, L5M 2N1, Canada|Local Institution, Windsor, Ontario, N8W 2X3, Canada|Local Institution, Saskatoon, Saskatchewan, S7N 4H4, Canada|Local Institution, Quebec, G1V 4G2, Canada|Local Institution, Québec, G1R 2J6, Canada|Local Institution, Bayonne, 64100, France|Local Institution, Besancon, 25000, France|Local Institution, Boulogne sur Mer, 62200, France|Local Institution, Boulogne, 92104, France|Local Institution, Brest Cedex, 29609, France|Local Institution, Clermont Ferrand Cédex 1, 63003, France|Local Institution, Dijon, 21079, France|Local Institution, Grenoble Cédex, 38043, France|Local Institution, Lille Cedex, 59037, France|Local Institution, Limoges Cedex, 87042, France|Local Institution, Montauban, 82000, France|Local Institution, Mougins, 06250, France|Local Institution, Nouvelle Caledonie, 98849, France|Local Institution, Paris Cedex 10, 75475, France|Local Institution, Pierre Bénite, 69495, France|Local Institution, Quimper Cedex, 29107, France|Local Institution, Quimper, 29107, France|Local Institution, Soissons cedex, 02209, France|Local Institution, Strasbourg Cedex, 67065, France|Local Institution, Vandoeuvre Les Nancy, 54500, France|Local Institution, Augsburg, 86156, Germany|Local Institution, Bochum, 44791, Germany|Local Institution, Buxtehude, 21614, Germany|Local Institution, Chemnitz, 09117, Germany|Local Institution, Darmstadt, 64297, Germany|Local Institution, Dessau-Roblau, 06847, Germany|Local Institution, Dortmund, 44137, Germany|Local Institution, Dresden, 01307, Germany|Local Institution, Düsseldorf, 40225, Germany|Local Institution, Frankfurt, 60590, Germany|Local Institution, Gera, 07548, Germany|Local Institution, Halle/Saale, 06120, Germany|Local Institution, Hamburg, 20099, Germany|Local Institution, Hamburg, 20246, Germany|Local Institution, Hamburg, 20253, Germany|Local Institution, Hannover, 30625, Germany|Local Institution, Jena, 07743, Germany|Local Institution, Koblenz, 56068, Germany|Local Institution, Lüdenscheid, 58515, Germany|Local Institution, Magdeburg, 39120, Germany|Local Institution, Mainz, 55131, Germany|Local Institution, Mannheim, 68167, Germany|Local Institution, Marburg, 35043, Germany|Local Institution, Münster, 48149, Germany|Local Institution, Plauen, 08529, Germany|Local Institution, Quedlinburg, 06484, Germany|Local Institution, Recklinghausen, 45657, Germany|Local Institution, Rostock, 18055, Germany|Local Institution, Schwäbisch Hall, 74523, Germany|Local Institution, Stuttgart, 70374, Germany|Local Institution, Tübingen, 72076, Germany|Local Institution, Würzburg, 97080, Germany|Local Institution, Cholargos, Athens, 15562, Greece|Local institution, Goudi, Athens, 11527, Greece|Local Institution, Neo Faliro, Athens, 18547, Greece|Local Institution, Heraklion, Crete, 71100, Greece|Local Institution, Neas Efkarpia, Thessaloniki, 56429, Greece|Local Institutio, Alexandroupolis, 68100, Greece|Local Institution, Athens, 11528, Greece|Local Institution, Athens, 15233, Greece|Local Institution, Mezourlo, 41334, Greece|Local Institution, Neo Faliro, 18547, Greece|Local Institution, Wilton, Cork, T12 DC4A, Ireland|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Tullamore, Ireland|Local Institution, Haifa, 31096, Israel|Local Institution, Tel Aviv, 64239, Israel|Local Institution, Tel Hashomer, 52621, Israel|Local Institution, Bydgoszcz, 85-796, Poland|Local Institution, Warszawa, 02-781, Poland|Local Institution, Wrocław, 51-124, Poland|Local Institution, Łódź, 93-510, Poland|Local Institution, Barcelona, 08036, Spain|Local Institution, Donostia, 20014, Spain|Local Institution, Las Palmas de Gran Canaria, 35016, Spain|Local Institution, Madrid, 28007, Spain|Local Institution, Madrid, 28033, Spain|Local Institution, Madrid, 28034, Spain|Local Institution, Madrid, 28041, Spain|Local Institution, Palma de Mallorca, 07198, Spain|Local Institution, Palma, 07198, Spain|Local Institution, Pamplona, 31008, Spain|Local Institution, Santa Cruz de Tenerife, 38010, Spain|Local Institution, Santander, 39008, Spain|Local Institution, Santiago De Compostela; A Coruña, 15706, Spain|Local Institution, Sevilla, 41013, Spain|Local Institution, Sta Cruz de Tenerife, 35320, Spain|Local Institution, Terrassa, 08027, Spain|Local Institution, Valladolid, 47012, Spain|Local Institution, Zaragoza, 50009, Spain|Local Institution, Baden, CH-5404, Switzerland|Local Institution, Lugano, CH-6900, Switzerland|Local Institution, Zurich, 8091, Switzerland|Local Institution, Zürich, CH-8091, Switzerland|Local Institution, Rhyl, Denbigshire, LL18 5UJ, United Kingdom|Local Institution, London, England, NW3 2QG, United Kingdom|Local Institution, Chelmsford, Essex, Essex, CM1 7ET, United Kingdom|Local Institution, Southend, Essex, SS0 0RY, United Kingdom|Local Institution, Belfast, Ireland, BT9 7AB, United Kingdom|Local Institution, Cardiff, South Glamorgan, CF14 2TL, United Kingdom|Local Institution, Birmingham, B15 2TH, United Kingdom|Local Institution, Bristol, BS2 8ED, United Kingdom|Local Institution, Exeter, EX2 5DW, United Kingdom|Local Institution, Hull, HU16 5JQ, United Kingdom|Local Institution, Leeds, LS9 7TF, United Kingdom|Local Institution, Lincoln, LN2 5QY, United Kingdom|Local Institution, London, SE1 9RT, United Kingdom|Local Institution, London, SW3 6JJ, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Oxfordshire, OX3 7LE, United Kingdom|Local Institution, Plymouth, PL6 8DH, United Kingdom|Local Institution, Poole, BH15 2JB, United Kingdom|Local Institution, Preston, PR2 9HT, United Kingdom|Local Institution, Staffordshire, ST46QG, United Kingdom|Local Institution, Taunton, Somerset, TA1 5DA, United Kingdom|Local Institution, Truro, Cornwall, TR1 3LJ, United Kingdom|Local Institution, Wirral, CH63 4JY, United Kingdom|Local Institution, Wolverhampton, WS13 6NH, United Kingdom|Local Institution, Yeovil, Somerset, BA21 4AT, United Kingdom"
NCT01990248,An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS),https://clinicaltrials.gov/study/NCT01990248,NO,Malignant Melanoma,,ALL,"ADULT, OLDER_ADULT",,"LKH Feldkirch; Onkologie, Feldkirch, 6800, Austria|Ordensklinikum Linz Elisabethinen ; Dermatologie, Linz, 4020, Austria|Krankenhaus Hietzing Wien, Wien, 1130, Austria|ZNA Middelheim, Antwerpen, 2020, Belgium|CHIREC Edith Cavell, Bruxelles, 1180, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|FN Ostrava; Dermatology dep, Ostrava, 708 52, Czechia|University Hospital Prague, Praha, 150 06, Czechia|Komplexni onkologicke centrum Krajske nemocnice T. Bati, a.s. Zlin, Zlin, 760 01, Czechia|Klinikum Augsburg; Hauttumorzentrum, Augsburg, 86179, Germany|Charite- universitatsmedizin Berlin; Med. Klinik mit Schwerpunkt Hamatologie und Onkologie, Berlin, 12200, Germany|Ruhr-Universität Bochum; Klinik für Dermatologie und Allergologie, Bochum, 44791, Germany|Universitatsklinikum Bonn; Klinisches Studienzentrum Klinik fur Dermatologie, Bonn, 53105, Germany|Medizinisches Zentrum, Bonn, 53111, Germany|Dermatologisches Zentrum am Elbe Klinikum Buxtehude, Buxtehude, 21614, Germany|DRK Krankenhaus Chemnitz-Rabenstein; Hautkrebszentrum Chemnitz, Chemnitz, 09117, Germany|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik fur Dermatologie, Dresden, 01307, Germany|Universitätsklinikum Düsseldorf; Hautklinik, Düsseldorf, 40225, Germany|Dermatologie und Allergologie HELIOS Hauttumorzentrum Erfurt, Erfurt, 99089, Germany|Universitatsklinikum Essen; Klinik für Dermatologie, Essen, 45147, Germany|SRH Wald-Klinikum Gera; Zentrum fur klinische Studien (ZKS), Gera, 07548, Germany|Universitätsmedizin Greifswald; Klinik und Poliklinik für Hautkrankheiten, Greifswald, 17487, Germany|Universitaetsmedizin Goettingen; Abteilung Dermato-Onkologie, Göttingen, 37075, Germany|Univ.- Hautklinik Heidelberg, Heidelberg, 69115, Germany|Friedrich-Schiller-Universitaet Jena; Klinik fuer Dermatologie und dermatologische Allergologie, Jena, 07743, Germany|Klinikum Kassel GmbH; Hauttumorzentrum HTZ, Kassel, 34125, Germany|Studienzentrum UnterEms; Onkologische Schwerpunktpraxis Leer; Dr. med. Lothar Müller, Leer, 26789, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH; Hauttumorzentrum Rheinpfalz, Ludwigshafen, 67063, Germany|UKSH Universitatsklinikum Schleswig-Holstein; Studienzentrum Dermatologie 10d, Lübeck, 23538, Germany|Klinik und Poliklinik fur Dermatologie; Universitatsklinikum Mainz, Mainz, 55131, Germany|Med. Fakultat Mannheim der Universitat Heidelberg; Klinik fur Dermatologie, Mannheim, 68167, Germany|Johannes Wesling Klinikum Minden;Haut Tumor Centrum Minden, Minden, 32429, Germany|Universitätsklinikum Münster; Klinik für Hautkrankheiten; Allgemeine Dermatologie und Venerologie, Muenster, 48149, Germany|Fachklinik Hornheide; Abteilung für Dermatologie, Muenster, 48157, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, 90419, Germany|Harzklinikum Dorothea Christiane Erxleben GmbH, Standort Quedlinburg; Hautkrebszentrum Harz, Quedlinburg, 06484, Germany|Klinikum Vest; Behandlungszentrum Kanppschaftskrankenhaus Recklinghausen, Recklinghausen, 45657, Germany|Universitätsmedizin Rostock; Klinik und Poliklinik für Dermatologie und Venerologie, Rostock, 18057, Germany|Eberhard-Karls-Universitat Tubingen; Sektion Dermatologische Onkologie, Tuebingen, 72076, Germany|Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, 97080, Germany|Galway University Hospital; Clinical Trials Department, Galway, Ireland|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, 80131, Italy|Policlinico S. Orsola Malpighi;Dip. Ematologia, Oncologia e Medicina di Laboratorio, Bologna, Emilia-Romagna, 40138, Italy|Ausl Ravenna-Osp.Infermi; Day Hospital Oncologia Medica, Faenza, Emilia-Romagna, 48018, Italy|Universita di Modena e Reggio Emilia;Dipartimento di Oncologia ed Ematologia, Modena, Emilia-Romagna, 41100, Italy|Ospedale ""Guglielmo da Saliceto"";U.O. Medicina Oncologica, Piacenza, Emilia-Romagna, 29121, Italy|Azienda ASL di Rimini (Presidi di Rimini - Cattolica)) - Ospedale degli Infermi;U.O. Oncologia, Rimini, Emilia-Romagna, 47922, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, 20133, Italy|Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milano, Lombardia, 20162, Italy|Fondazione IRCCS Policlinico San Matteo, Oncologia, Pavia, Lombardia, 27100, Italy|A.O.V.V. - P.O. di Sondrio; S.O.C. Oncologia Medica, Sondrio, Lombardia, 23100, Italy|A.U Careggi di Firenze;Oncologia, Firenze, Toscana, 50134, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Toscana, 56100, Italy|Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena, Toscana, 53100, Italy|Amphia Ziekenhuis, locatie Langendijk;Oncology, Breda, 4819 EV, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, 9713 GZ, Netherlands|Atrium MC, Parkstad Heerlen; Poli Interne, Heerlen, 6419 PC, Netherlands|Maastricht University Medical Center,Division of Medical Oncology; Dept. Internal Medicine, Maastricht, 6229 HX, Netherlands|Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii, Bydgoszcz, 85-796, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Krakow, 31-531, Poland|RegioNAlny Osrodek Onkologiczny Pododdział Diagnostyki i Terapii Onkologicznej, Lodz, 93-513, Poland|Regionalny Osrodek Onkologiczny; Oddzial Chorob Rozrostowych, Lodz, 93-513, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej; Opolskie Centrum Onkologii, Opole, 45-060, Poland|Centrum Onkologii - Instytut, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, 02-781, Poland|Blekingesjukhuset; Kirurgkliniken, Karlskrona, 371 85, Sweden|Karolinska University Hospital;Department of Oncology-Pathology, Stockholm, 17176, Sweden|Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, United Kingdom|Addenbrookes Hospital; Dept of Oncology, Cambridge, CB2 2QQ, United Kingdom|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Cheltenham General Hospital; Gloucestershire Oncology Centre, Cheltenham, GL53 7AN, United Kingdom|Dorset County Hospital NHS Foundation Trust;Research and Development/ Oncology, Dorchester, DT1 2JY, United Kingdom|St James University Hospital, Leeds, LS9 7TF, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, SE1 9RT, United Kingdom|St George's Hospital; Oncology, London, SW17 0QT, United Kingdom|Imperial College Healthcare NHS Trust;Medical Oncology, London, W6 8RF, United Kingdom|St Helens & Knowsley Trust, St Helens, WA9 3DA, United Kingdom|The Clatterbridge Cancer Ctr For Oncolgy, Wirral, CH63 4JY, United Kingdom|New Cross Hospital; Deansley Centre, Wolverhampton, WV10 0QP, United Kingdom"
NCT01898585,An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01898585,NO,Malignant Melanoma,DRUG: Zelboraf,ALL,"ADULT, OLDER_ADULT",PHASE4,"National Hospital; Oncotherapy Dept, Bloemfontein, 9301, South Africa|Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town, 7506, South Africa|Cape Town Oncology Trials, Cape Town, 7570, South Africa|Cancercare, Cape Town, 7700, South Africa|Cancercare, George, 6529, South Africa|Mary Potter Oncology Centre, Groenkloof, 0181, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, 2196, South Africa|University of Pretoria; Department of Medical Oncology, Pretoria, 0002, South Africa|Sandton Oncology Medical Group, Sandton, 2196, South Africa"
NCT01910181,A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01910181,YES,Malignant Melanoma,DRUG: Vemurafenib,ALL,"ADULT, OLDER_ADULT",PHASE1,"Beijing Cancer Hospital, Beijing, 100142, China|Sun Yet-sen University Cancer Center, Guangzhou, 510060, China"
NCT01744860,Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples,https://clinicaltrials.gov/study/NCT01744860,YES,Malignant Melanoma,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Boulogne Billancourt, 92104, France|Colmar, 68024, France|Lille, 59037, France|Lyon, 69437, France|Marseille, 13015, France|Montpellier, 34295, France|Nantes, 44093, France|Paris, 75010, France|Pessac, 33604, France|Rouen, 76031, France|Vandoeuvre Les Nancy, 54511, France|Villejuif, 94505, France"
NCT00145145,Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00145145,YES,Malignant Melanoma,BIOLOGICAL: MAGE-3.A1 peptide and CpG 7909,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Cliniques Universitaires Saint-Luc (UCL), Brussels, B-1200, Belgium|Ludwig Institute for Cancer Research, Brussels, B-1200, Belgium"
NCT01164007,A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01164007,YES,Malignant Melanoma,DRUG: Bevacizumab|DRUG: Dacarbazine,ALL,"ADULT, OLDER_ADULT",PHASE2,"Istituto Europeo Di Oncologia, Milano, Lombardia, 20141, Italy"
NCT00949702,A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT00949702,YES,Malignant Melanoma,DRUG: vemurafenib,ALL,"ADULT, OLDER_ADULT",PHASE2,"UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, 90095-6984, United States|University of Colorado, Denver, Colorado, 80262, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Massachusetts General Hospital;Hematology/ Oncology, Boston, Massachusetts, 02114, United States|Dana Farber Cancer Inst. ; Dept. of Medical Oncology, Boston, Massachusetts, 02115, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|New York University Medical Center, New York, New York, 10036, United States|Hospital of the Uni of Pennsylvania; Section of Hematology/Oncology, Philadelphia, Pennsylvania, 19104-4283, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, 37232, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Calvary Mater Newcastle; Melanoma Clinic, Newcastle, New South Wales, 2298, Australia|Westmead Hospital; Medical Oncology and Pallative Care, Westmead, New South Wales, 2145, Australia|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, 3000, Australia"
NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00052156,NO,Malignant Melanoma,BIOLOGICAL: CancerVax vaccine (CANVAXIN),ALL,"ADULT, OLDER_ADULT",PHASE3,"Arizona Cancer Center, Tucson, Arizona, 85724, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, 72205, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Kaiser Permanente Medical Group, Anaheim, California, United States|Cedars Sinai Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92658, United States|Comprehensive Cancer Center at DRMC, Palm Springs, California, 92262, United States|Kaiser Permanente Medical Group, Riverside, California, United States|Kaiser Permanente Medical Group, San Diego, California, 92120, United States|Sharp Hospital, San Diego, California, 92123, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94143-0128, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Lakeland Regional Cancer Center, Lakeland, Florida, 33805, United States|Mt. Sinai Comprehensive Cancer Center, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612-9497, United States|The Cancer Institute at Good Samaritan Medical Center, West Palm Beach, Florida, 33401, United States|Loyola University Medical Center, Maywood, Illinois, United States|OSF Saint Francis Medica Center, Peoria, Illinois, 61637, United States|Wagner and Associates, Indianapolis, Indiana, 46256, United States|James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|St. Agnes Healthcare, Baltimore, Maryland, 21229, United States|Franklin Square Hospital Center, Baltimore, Maryland, 21237, United States|Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, 02118-2393, United States|Spectrum Health - Butterworth Campus, Grand Rapids, Michigan, 49546, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, 65203, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, 63110-0250, United States|The Cancer Cener at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Medical Center of Princeton, Princeton, New Jersey, 08540, United States|Millard Fillmore Hospital, Buffalo, New York, 14209, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States|Columbia Presbyterian Medical Center, New York, New York, 10032, United States|Suny Health Science Center at Syracuse, Syracuse, New York, 13210, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, 27599-7295, United States|Wake Forest University, Winston Salem, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, 45219, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, 43210-1240, United States|Dayton Clinical Oncology Group, Dayton, Ohio, 45409, United States|St. Lukes Hospital Cancer Center, Bethlehem, Pennsylvania, 18015, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, 19104-4283, United States|Lankenau Hospital, Wynnewood, Pennsylvania, 19096, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232-6838, United States|UT Southwest Medical Center- Dallas, Dallas, Texas, 75235-9154, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Intermountain Health Care- Mckay-Dee Hospital, Ogden, Utah, 84403, United States|Intermountain Health Care-LDS Hospital, Salt Lake City, Utah, 84143, United States|University of Washington, Seattle, Washington, 98109, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, 2050, Australia|NSW Breast Cancer Institute, Westmead, New South Wales, 2145, Australia|Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, 3002, Australia|The Alfred Hospital, Melbourne, Victoria, 3181, Australia|INCA (National Cancer Institute), Rio de Janeiro, 20230, Brazil|Hospital Sirio Lebanes, Sao Paulo, 01308-050, Brazil|McGill University, Montreal, Quebec, Canada|CHU Pitie-Salpetriere, Paris, 75651, France|Klinikum Augsburg, Augsburg, Germany|Charite- University Medicine, Berlin, Germany|University of Jena, Jena, 07740, Germany|University Hospial of Mannheim, Mannheim, Germany|University of Tuebingen, Tuebingen, Germany|University of Ulm, Ulm, Germany|University Hospital Wuerzburg, Wuerzburg, Germany|Cork University, Cork, Ireland|Tel-Aviv Medical Center, Tel Aviv, 62995, Israel|Istituto Nazionale Tumori di Milano, Milan, 20133, Italy|Instituto Eurepeo di Oncologia, Milan, 20141, Italy|Istituto Nazionale dei Tumori, Naples, 80132, Italy|University Hospital of Groningen, Groningen, Netherlands|North Shore Hospital, Auckland, 92024, New Zealand|University of Zurich, Zurich, Switzerland|Harley Street Clinic, London, England, SW17 ORE, United Kingdom"
NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,https://clinicaltrials.gov/study/NCT00052130,NO,Malignant Melanoma,BIOLOGICAL: CancerVax vaccine (CANVAXIN),ALL,"ADULT, OLDER_ADULT",PHASE3,"Arizona Cancer Center, Tucson, Arizona, 85724, United States|Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, 72205, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States|Kaiser Permanente Medical Group, Anaheim, California, United States|Cedars Sinai Comprehensive Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, 92658, United States|Comprehensive Cancer Center at DRMC, Palm Springs, California, 92262, United States|Kaiser Permanente Medical Group, Riverside, California, United States|Kaiser Permanente Medical Group, San Diego, California, 92120, United States|Sharp Hospital, San Diego, California, 92123, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, 94143-0128, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Lakeland Regional Cancer Center, Lakeland, Florida, 33805, United States|Mt. Sinai Comprehensive Cancer Center, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612-9497, United States|The Cancer Institute at Good Samaritan Medical Center, West Palm Beach, Florida, 33401, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, 30322, United States|Loyola University Medical Center, Maywood, Illinois, United States|OSF Saint Francis Medica Center, Peoria, Illinois, 61637, United States|Cancer Care of Southern Indiana, Bloomington, Indiana, 47402, United States|Wagner and Associates, Indianapolis, Indiana, 46256, United States|James Graham Brown Cancer Center, Louisville, Kentucky, 40202, United States|St. Agnes Healthcare, Baltimore, Maryland, 21229, United States|Franklin Square Hospital Center, Baltimore, Maryland, 21237, United States|Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, 02118-2393, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Spectrum Health - Butterworth Campus, Grand Rapids, Michigan, 49546, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, 65203, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, 63110-0250, United States|The Cancer Cener at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Medical Center of Princeton, Princeton, New Jersey, 08540, United States|Millard Fillmore Hospital, Buffalo, New York, 14209, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States|Columbia Presbyterian Medical Center, New York, New York, 10032, United States|Suny Health Science Center at Syracuse, Syracuse, New York, 13210, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, 27599-7295, United States|Christ Hospital, Cincinnati, Ohio, 45219, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, 43210-1240, United States|Dayton Clinical Oncology Group, Dayton, Ohio, 45409, United States|St. Lukes Hospital Cancer Center, Bethlehem, Pennsylvania, 18015, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, 19104-4283, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Lankenau Hospital, Wynnewood, Pennsylvania, 19096, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, 37232-6838, United States|UT Southwest Medical Center- Dallas, Dallas, Texas, 75235-9154, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|Intermountain Health Care- Mckay-Dee Hospital, Ogden, Utah, 84403, United States|Intermountain Health Care-LDS Hospital, Salt Lake City, Utah, 84143, United States|University of Washington, Seattle, Washington, 98195, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, 2050, Australia|NSW Breast Cancer Institute, Westmead, New South Wales, 2145, Australia|Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, 3002, Australia|The Alfred Hospital, Melbourne, Victoria, 3181, Australia|INCA (National Cancer Institute), Rio de Janeiro, 20230, Brazil|Hospital Sirio Lebanes, Sao Paulo, 01308-050, Brazil|McGill University, Montreal, Quebec, Canada|CHU Pitie-Salpetriere, Paris, 75651, France|Klinikum Augsburg, Augsburg, Germany|Charite- University Medicine, Berlin, Germany|University of Jena, Jena, Germany|University Hospial of Mannheim, Mannheim, Germany|University of Tuebingen, Tuebingen, Germany|University of Ulm, Ulm, Germany|University Hospital Wuerzburg, Wuerzburg, Germany|Cork University, Cork, Ireland|Tel-Aviv Medical Center, Tel Aviv, 62995, Israel|Istituto Nazionale Tumori di Milano, Milan, 20133, Italy|Instituto Eurepeo di Oncologia, Milan, 20141, Italy|Istituto Nazionale dei Tumori, Naples, 80132, Italy|University Hospital of Groningen, Groningen, Netherlands|North Shore Hospital, Auckland, 92024, New Zealand|University of Zurich, Zurich, Switzerland|St. Georges Hospital Medical School, London, England, SW17 ORE, United Kingdom"
NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,https://clinicaltrials.gov/study/NCT00039000,NO,Malignant Melanoma,DRUG: HSPPC-96 or Oncophage,ALL,"ADULT, OLDER_ADULT",PHASE3,"Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Berkeley, California, United States|Los Angeles, California, United States|Stanford, California, United States|Vista, California, United States|Denver, Colorado, United States|Farmington, Connecticut, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Miami Beach, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Robbinsdale, Minnesota, United States|Rochester, Minnesota, United States|Columbia, Missouri, United States|St. Louis, Missouri, United States|Lebanon, New Hampshire, United States|New Brunswick, New Jersey, United States|New York City, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Madison, Wisconsin, United States|Adelaide, Australia|Camperdown, Australia|Melbourne, Australia|Newcastle, Australia|Wentworthville, Australia|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szeged, Hungary|Aviano, Italy|Genova, Italy|Milan, Italy|Rimini, Italy|Bialystock, Poland|Bydgoszcz, Poland|Krakow, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Ryazan, Russian Federation|Samara, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Voronezh, Russian Federation|Gothenburg, Sweden|Lund, Sweden|Vaxjo, Sweden|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankovsk, Ukraine|Kiev, Ukraine|Krivoy Rog, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom"
NCT01069627,A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01069627,YES,Malignant Melanoma,DRUG: bevacizumab [Avastin]|DRUG: fotemustine,ALL,"ADULT, OLDER_ADULT",PHASE2,"Firenze, 50100, Italy|Genova, 16132, Italy|Milano, 20133, Italy|Torino, 10126, Italy"
NCT01164891,A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01164891,YES,Malignant Melanoma,DRUG: RO5185426,ALL,"ADULT, OLDER_ADULT",PHASE1,"Zürich, 8091, Switzerland"
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,https://clinicaltrials.gov/study/NCT01253564,YES,Malignant Melanoma,DRUG: RO5185426,ALL,"ADULT, OLDER_ADULT",PHASE2,"CHUV; Departement d'Oncologie, Lausanne, 1011, Switzerland|Universitätsspital Zürich; Dermatologische Klinik, Zürich, 8091, Switzerland"
NCT01107418,A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01107418,YES,Malignant Melanoma,DRUG: RO5185426|DRUG: RO5185426|DRUG: RO5185426|DRUG: RO5185426|DRUG: RO5185426,ALL,"ADULT, OLDER_ADULT",PHASE1,"La Jolla, California, 92093, United States|San Francisco, California, 94115, United States|Stanford, California, 94305, United States|New Haven, Connecticut, 06510-3289, United States|Chicago, Illinois, 60637, United States|Park Ridge, Illinois, 60068, United States|Sioux City, Iowa, 51101, United States|Omaha, Nebraska, 68114, United States|Columbus, Ohio, 43219, United States|East Providence, Rhode Island, 02915, United States|Charlottesville, Virginia, 22908, United States|Adelaide, South Australia, 5000, Australia|Melbourne, Victoria, 3181, Australia"
NCT01519323,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,https://clinicaltrials.gov/study/NCT01519323,YES,Malignant Melanoma,DRUG: vemurafenib,ALL,CHILD,PHASE1,"Los Angeles, California, 90027, United States|Aurora, Colorado, 80045, United States|St. Petersburgh, Florida, 33701, United States|Bethesda, Maryland, 20892, United States|Boston, Massachusetts, 02115, United States|New York, New York, 10065, United States|Memphis, Tennessee, 38105, United States|Houston, Texas, 77030, United States|Westmead, New South Wales, 2145, Australia|Brisbane, Queensland, 4029, Australia|Marseille, 13385, France|Pierre Benite, 69495, France|Kiel, 24116, Germany|Mainz, 55101, Germany|Tuebingen, 72076, Germany|Jerusalem, 9112001, Israel|Petach-Tikva, 49100, Israel|Roma, Lazio, 00165, Italy|Genova, Liguria, 16147, Italy|Milano, Lombardia, 20133, Italy|Wroclaw, 50-367, Poland|Bratislava, 83340, Slovakia|Esplugues De Llobregas, Barcelona, 08950, Spain|Sevilla, 41013, Spain|Newcastle upon Tyne, NE1 4LP, United Kingdom|Sutton, SM2 5PT, United Kingdom"
NCT01378975,A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases,https://clinicaltrials.gov/study/NCT01378975,YES,Malignant Melanoma,DRUG: Vemurafenib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Los Angeles, California, 90025, United States|Aurora, Colorado, 80045, United States|Tampa, Florida, 33612-9497, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48201, United States|Rochester, Minnesota, 55905, United States|Saint Louis, Missouri, 63110, United States|Charlotte, North Carolina, 28204-2839, United States|Dallas, Texas, 75246, United States|Seattle, Washington, 98195, United States|Wentworthville, New South Wales, 2145, Australia|Melbourne, Victoria, 3002, Australia|Toronto, Ontario, M4N 3M5, Canada|Bordeaux, 33075, France|Nice, 06202, France|Paris, 75006, France|Paris, 75475, France|Essen, 45122, Germany|Frankfurt, 60596, Germany|Kiel, 24105, Germany|Mannheim, 68167, Germany|Münster, 48157, Germany|Tübingen, 72076, Germany|Tel-Hashomer, 52621, Israel|Milano, Lombardia, 20133, Italy|Siena, Toscana, 53100, Italy|Amsterdam, 1066 CX, Netherlands|Groningen, 9713 GZ, Netherlands|Pamplona, Navarra, 31008, Spain|Barcelona, 08036, Spain|Madrid, 28046, Spain|Northwood, HA6 2RN, United Kingdom"
NCT05620290,MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer,https://clinicaltrials.gov/study/NCT05620290,NO,Melanoma,DRUG: Definity|DEVICE: Sonalleve Focused Ultrasound Device,ALL,"ADULT, OLDER_ADULT",PHASE1,"Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada"
NCT03493230,Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ),https://clinicaltrials.gov/study/NCT03493230,NO,Malignant Melanoma Stage IV|Malignant Melanoma Stage III,BIOLOGICAL: quantification of BRAF and NRAS mutation,ALL,"ADULT, OLDER_ADULT",NA,
NCT01586195,"Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",https://clinicaltrials.gov/study/NCT01586195,YES,Malignant Melanoma,DRUG: Vemurafenib,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,"Arizona Cancer Center, Tucson, Arizona, 85724, United States|UCSD Moores Cancer Center, La Jolla, California, 92093, United States|UCLA School of Medicine; Hematology/Oncology, Los Angeles, California, 90095, United States|The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, 90025, United States|University of Colorado; Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Emory University; Winship Cancer Institute, Atlanta, Georgia, 30308, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Atlantic Health System, Morristown, New Jersey, 07960, United States|Columbia University Medical Center, New York, New York, 10032, United States|Mid Ohio Onc Hematology Inc, Columbus, Ohio, 43219, United States|UPCI Cancer Institute; Cancer Pavillion, Pittsburgh, Pennsylvania, 15232, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, 37232, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States"
NCT05628883,"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma",https://clinicaltrials.gov/study/NCT05628883,NO,Metastatic Melanoma|Unresectable Melanoma|Acral Melanoma|Mucosal Melanoma|Cutaneous Melanoma|Ocular Melanoma|Uveal Melanoma|Iris Melanoma|Conjunctival Melanoma|Non-Cutaneous Melanoma,BIOLOGICAL: TBio-4101|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2,ALL,"ADULT, OLDER_ADULT",PHASE1,"Moffitt Cancer Center, Tampa, Florida, 33612, United States"
NCT00826995,Comparison of Video-Based Versus Written Patient Education on Melanoma,https://clinicaltrials.gov/study/NCT00826995,NO,Melanoma|Malignant Melanoma,OTHER: Patient Educational Materials,ALL,"ADULT, OLDER_ADULT",NA,"University of California Davis Department of Dermatology, Sacramento, California, 95816, United States"
NCT00616564,Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma,https://clinicaltrials.gov/study/NCT00616564,NO,Malignant Melanoma,DRUG: GM-CSF,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE2,"Jose Lutzky, MD, Miami Beach, Florida, 33140, United States|David Lawson, MD, Atlanta, Georgia, 30322, United States"
NCT01001299,A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01001299,YES,Malignant Melanoma,DRUG: Drug cocktail|DRUG: RO5185426,ALL,"ADULT, OLDER_ADULT",PHASE1,"UCLA - School of Medicine, Los Angeles, California, 90095, United States|Massachusetts General Hospital;Hematology/ Oncology, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, 37232, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, 75246, United States"
NCT01006980,A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3),https://clinicaltrials.gov/study/NCT01006980,YES,Malignant Melanoma,DRUG: Vemurafenib|DRUG: Dacarbazine,ALL,"ADULT, OLDER_ADULT",PHASE3,"Birmingham, Alabama, 35243, United States|Tucson, Arizona, 85724, United States|Los Angeles, California, 90095-1752, United States|San Francisco, California, 94117, United States|Santa Monica, California, 90404, United States|Aurora, Colorado, 80045, United States|Atlanta, Georgia, 30322, United States|Indianapolis, Indiana, 46202, United States|Boston, Massachusetts, 02114, United States|Boston, Massachusetts, 02115, United States|Boston, Massachusetts, 02215, United States|Detroit, Michigan, 48201, United States|St Louis, Missouri, 63110, United States|New York, New York, 10016, United States|New York, New York, 10065, United States|Chapel Hill, North Carolina, 27514, United States|Portland, Oregon, 97213, United States|Philadelphia, Pennsylvania, 19104, United States|Pittsburgh, Pennsylvania, 15213-2584, United States|Nashville, Tennessee, 37203, United States|Nashville, Tennessee, 37232, United States|Dallas, Texas, 75246, United States|Salt Lake City, Utah, 84112, United States|Seattle, Washington, 98109, United States|Brisbane, 4006, Australia|Frankston, 3199, Australia|Malvern, 3144, Australia|Melbourne, 3002, Australia|Melbourne, 3128, Australia|Nedlands, 6009, Australia|Newcastle, 2310, Australia|St Leonards, 2065, Australia|Sydney, 2060, Australia|Westmead, 2145, Australia|Woolloongabba, 4102, Australia|Edmonton, Alberta, T5J 3N4, Canada|Winnipeg, Manitoba, R2H 2A6, Canada|Hamilton, Ontario, L8V 5C2, Canada|Toronto, Ontario, M4N 3M5, Canada|Toronto, Ontario, M5G 2M9, Canada|Montreal, Quebec, H3A 1A1, Canada|Montreal, Quebec, H3T 1E2, Canada|Quebec City, Quebec, G1R 2J6, Canada|Bordeaux, 33075, France|Lille, 59037, France|Marseille, 13005, France|Montpellier, 34298, France|Nantes, 44093, France|Nice, 06202, France|Paris, 75010, France|Pierre Benite, 69495, France|Rouen, 76031, France|Villejuif, 94805, France|Buxtehude, 21614, Germany|Dresden, 01307, Germany|Erfurt, 99089, Germany|Essen, 45122, Germany|Frankfurt, 60596, Germany|Hannover, 30449, Germany|Heidelberg, 69120, Germany|Jena, 07743, Germany|Kiel, 24105, Germany|Koeln, 50924, Germany|Leipzig, 04103, Germany|Mainz, 55131, Germany|Minden, 32429, Germany|Muenchen, 81377, Germany|Regensburg, 93053, Germany|Tuebingen, 72076, Germany|Wuerzburg, 80337, Germany|Jerusalem, 91200, Israel|Ramat Gan, 52621, Israel|Tel Aviv, 64239, Israel|Bari, 70124, Italy|Genova, 16132, Italy|Milano, 20133, Italy|Milano, 20141, Italy|Milano, 20162, Italy|Napoli, 80131, Italy|Roma, 00158, Italy|Siena, 53100, Italy|Amsterdam, 1066 CX, Netherlands|Amsterdam, 1081 HV, Netherlands|Groningen, 9713 GZ, Netherlands|Auckland, New Zealand|Dunedin, 9001, New Zealand|Hamilton, 2001, New Zealand|Palmerston North, New Zealand|Wellington, 6021, New Zealand|Linkoeping, 58185, Sweden|Lund, 22185, Sweden|Stockholm, 17176, Sweden|Umeå, Sweden|Uppsala, 75185, Sweden|Lausanne, 1011, Switzerland|Zürich, 8091, Switzerland|Cambridge, CB2 2QH, United Kingdom|Edinburgh, EH4 2XU, United Kingdom|Glasgow, G12 0YN, United Kingdom|London, E1 1BB, United Kingdom|London, NW3 2QG, United Kingdom|London, SE1 9RT, United Kingdom|London, SW3 3JJ, United Kingdom|Manchester, M20 4BX, United Kingdom|Newcastle Upon Tyne, NE7 7DN, United Kingdom|Northwood, HA6 2RN, United Kingdom|Nottingham, NG5 1PB, United Kingdom|Oxford, OX3 7LJ, United Kingdom|Southampton, SO16 6YD, United Kingdom|Sutton, SM2 5PT, United Kingdom|Swansea, SA2 8QA, United Kingdom"
NCT01271803,A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01271803,YES,Malignant Melanoma,DRUG: Cobimetinib|DRUG: vemurafenib,ALL,"ADULT, OLDER_ADULT",PHASE1,"UCLA Department of Medicine, Los Angeles, California, 90024, United States|University of California at San Francisco, San Francisco, California, 94115, United States|The Angeles Clinic and Research Institute, Santa Monica Office, Santa Monica, California, 90025, United States|University of Colorado; Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana University - Department of Medicine, Division of Gastroenterology/Hepatology, Indianapolis, Indiana, 46202, United States|Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building, Detroit, Michigan, 48201, United States|New York University Medical Center, New York, New York, 10036, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|Peter Maccallum Cancer Institute; Medical Oncology, Melbourne, Victoria, 3000, Australia"
NCT02938299,Neoadjuvant L19IL2/L19TNF- Pivotal Study,https://clinicaltrials.gov/study/NCT02938299,NO,Malignant Melanoma,DRUG: L19IL2 + L19TNF|PROCEDURE: Surgery,ALL,"ADULT, OLDER_ADULT",PHASE3,"Hôpital de la Timone, Marseille, 13 005, France|Hôpital Universitaire de Nantes, Nantes, 44 093, France|Institut Gustave Roussy, Villejuif, 94 805, France|Klinik für Dermatologie und Allergologie, Universitätsklinikum Augsburg, Augsburg, 86156, Germany|Charité Campus Mitte (CCM), Berlin, D-10117, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, D-01307, Germany|Klinik für Dermatologie, Medizinische Fakultät Universitätsklinikum Essen, Essen, 45122, Germany|Hauttumorzentrum Hannover (HTZH), Hannover, D-30625, Germany|Heidelberg University Hospital, Heidelberg, D-69120, Germany|Kiel University Hospital, Kiel, D-24105, Germany|Leipzig University Hospital, Leipzig, D-04103, Germany|Klinik und Polyklinik für Dermatologie, Universitätsklinikum Regensburg, Regensburg, 93042, Germany|Tübingen University Hospital, Tübingen, D-72076, Germany|IRCCS A.O.U. San Martino - IST, Genova, 16132, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Naples, 80131, Italy|Istituto Oncologico Veneto, IRCCS, Padova, 35128, Italy|AOU Senese, Siena, 53100, Italy|ASUGI Trieste, Trieste, 34128, Italy|AOU Città della Salute e della Scienza, Turin, 10126, Italy|Medgart Centrum Medyczne, Gdańsk, 80-980, Poland|Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa, Warsaw, 02-781, Poland"
NCT05900102,EVALUATING THE CURRENT STANDARD OF CARE FOR PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA OF THE HEAD AND NECK - ACCESS TO STAGING AND SURGICAL TREATMENT,https://clinicaltrials.gov/study/NCT05900102,NO,Melanoma (Skin)|Melanoma,,ALL,"ADULT, OLDER_ADULT",,
NCT04293289,Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma,https://clinicaltrials.gov/study/NCT04293289,NO,Malignant Melanoma|Angiosarcoma,"OTHER: CICS-1 (investigational device),SPM-011(investigational drug)",ALL,"ADULT, OLDER_ADULT",NA,"National Cancer Center Hospital, Chuo Ku, Tokyo, 104-0045, Japan"
NCT00204607,Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients,https://clinicaltrials.gov/study/NCT00204607,NO,Malignant Melanoma,BIOLOGICAL: mRNA|DRUG: GM-CSF s.c.,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Department of Dermatology, University of Tübingen, Tübingen, 72076, Germany"
NCT02143999,An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma,https://clinicaltrials.gov/study/NCT02143999,NO,Malignant Melanoma,,ALL,"ADULT, OLDER_ADULT",,"Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica, Chieti, Abruzzo, 66100, Italy|IRCCS IST. Tumori Fondaz. Pascale; S.C. Oncologia Medica,Melanoma,Immunoterapia E Terapie Innovative, Napoli, Campania, 80131, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, 40138, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST);U.O. di Immunoterapia, Meldola, Emilia-Romagna, 47014, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, 42100, Italy|Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica, Roma, Lazio, 00128, Italy|Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, 00161, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, 24128, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, 25123, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (Ieo); Unita' Di Ricerca Traslazionale Del Melanoma, Milano, Lombardia, 20141, Italy|Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo, Candiolo, Piemonte, 10060, Italy|Azienda Sanitaria Ospedaliera s. Croce e Carle; Oncologia Medica, Cuneo, Piemonte, 12100, Italy|Ospedale Maggiore Della Carita; Oncologia Medica, Novara, Piemonte, 28100, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, 10126, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Puglia, 70124, Italy|Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1, Palermo, Sicilia, 90127, Italy|Ospedale S. Vincenzo; Oncologia Medica, Taormina, Sicilia, 98030, Italy|Azienda Sanitaria di Firenze Presidio Palagi - SC Dermatologia II e Fisioterapia Dermatologica, Firenze, Toscana, 50125, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, 56100, Italy|Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena, Toscana, 53100, Italy|Azienda Ospedaliero Universitaria di Ferrara - U.O. Di Oncologia, Cona (FE), Veneto, 44124, Italy|Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Oncologia Medica, Verona, Veneto, 37134, Italy"
NCT02296996,Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients,https://clinicaltrials.gov/study/NCT02296996,NO,Malignant Melanoma,DRUG: Dabrafenib + Trametinib,ALL,"ADULT, OLDER_ADULT",PHASE2,"UZ Brussel, Brussels, 1090, Belgium"
NCT00204516,Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens,https://clinicaltrials.gov/study/NCT00204516,NO,Malignant Melanoma,BIOLOGICAL: mRNA coding for melanoma associated antigens|DRUG: GM-CSF,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Department of Dermatology, University of Tuebingen, Tuebingen, 72076, Germany"
NCT01264380,A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma,https://clinicaltrials.gov/study/NCT01264380,YES,Malignant Melanoma,DRUG: RO5185426|DRUG: RO5185426|DRUG: RO5185426,ALL,"ADULT, OLDER_ADULT",PHASE1,"La Jolla, California, 92037, United States|Los Angeles, California, 90095-1752, United States|San Francisco, California, 94115-1705, United States|Aurora, Colorado, 80045, United States|Indianapolis, Indiana, 46202, United States|Iowa City, Iowa, 52242, United States|Lebanon, New Hampshire, 03756, United States|Charleston, South Carolina, 29425, United States|Nashville, Tennessee, 37232, United States|Dallas, Texas, 75246, United States"
NCT00966173,International Melanoma Algorithm Training Study - IMATS,https://clinicaltrials.gov/study/NCT00966173,NO,Malignant Melanoma,DEVICE: SciBase III Electrical Impedance Spectrometer,ALL,"ADULT, OLDER_ADULT",NA,"Sahlgrenska University Hospital, Dpt. of Dermatology, Gothenburg, 41345, Sweden"
NCT04375527,Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma,https://clinicaltrials.gov/study/NCT04375527,NO,Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Locally Advanced Cutaneous Melanoma|Metastatic Cutaneous Melanoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Cutaneous Melanoma,DRUG: Binimetinib|BIOLOGICAL: Nivolumab|OTHER: Questionnaire Administration,ALL,"ADULT, OLDER_ADULT",PHASE2,"University of California at Los Angeles, Los Angeles, California, 90095, United States"
NCT06424626,A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma,https://clinicaltrials.gov/study/NCT06424626,NO,Melanoma|Mucosal Melanoma|Metastatic Melanoma,DRUG: AK104+Axitinib|DRUG: AK112+Axitinib,ALL,"ADULT, OLDER_ADULT",PHASE1,"Beijing Cancer Hospital, Beijing, 100142, China"
NCT01444560,"miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi",https://clinicaltrials.gov/study/NCT01444560,NO,Cutaneous Melanoma|Nevi,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, NRW, 44791, Germany"
NCT05645484,The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma,https://clinicaltrials.gov/study/NCT05645484,NO,Melanoma,DRUG: 18F-PFPN|DRUG: 18F-FDG,ALL,"ADULT, OLDER_ADULT",,"China, Hubei Province, Wuhan, Hubei, 430022, China"
NCT04460053,Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.,https://clinicaltrials.gov/study/NCT04460053,NO,Malignant Melanoma,PROCEDURE: Neurofilament light protein measurement in Isolated limb perfused patients,ALL,"ADULT, OLDER_ADULT",NA,"Sahlgrenska University Hospital, Gothenburg, 413 45, Sweden"
NCT00462423,"Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study",https://clinicaltrials.gov/study/NCT00462423,YES,Metastatic Malignant Melanoma,DRUG: Avastin|DRUG: Abraxane,ALL,"ADULT, OLDER_ADULT",PHASE2,"Northern California Melanoma Center, San Francisco, California, 94117, United States|The Angeles Clinic and Research Institute, Santa Monica, California, 90404, United States"
NCT01559818,A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001,https://clinicaltrials.gov/study/NCT01559818,YES,Malignant Melanoma,BIOLOGICAL: IMM-101,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"St Georges University of London, London, United Kingdom"
NCT04364230,Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma),https://clinicaltrials.gov/study/NCT04364230,NO,Melanoma|Ocular Melanoma|Uveal Melanoma,DRUG: 6MHP|DRUG: NeoAg-mBRAF|DRUG: PolyICLC|DRUG: CDX-1140,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States|University of Virginia, Charlottesville, Virginia, 22908, United States"
NCT03325101,Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery,https://clinicaltrials.gov/study/NCT03325101,NO,Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7,PROCEDURE: Cryosurgery|BIOLOGICAL: Pembrolizumab|PROCEDURE: Pheresis|BIOLOGICAL: Therapeutic Autologous Dendritic Cells,ALL,"ADULT, OLDER_ADULT",PHASE1|PHASE2,"Mayo Clinic, Rochester, Minnesota, 55905, United States"
NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,https://clinicaltrials.gov/study/NCT02574533,NO,Melanoma Recurrent|Malignant Melanoma|Melanoma,BIOLOGICAL: Vigil|DRUG: Pembrolizumab,ALL,"ADULT, OLDER_ADULT",PHASE1,"Texas Oncology P.A., Texas Cancer Center, Abilene, Texas, 79606, United States|Mary Crowley Medical Research Centers, Dallas, Texas, 75230, United States|Cancer Care Northwest, Spokane, Washington, 99202, United States"
NCT03409419,PET Imaging of the Immune System Using Analog Probes,https://clinicaltrials.gov/study/NCT03409419,NO,Malignant Melanoma,DRUG: [18F] CFA,ALL,"ADULT, OLDER_ADULT",,"University of California, Los Angeles, Los Angeles, California, 90095, United States"
NCT04548817,Neurocutaneous Melanocytosis Registry,https://clinicaltrials.gov/study/NCT04548817,NO,Cutaneous Melanocytic Neoplasm|Large Cutaneous Melanocytic Nevi|Neurocutaneous Melanocytosis,,ALL,"CHILD, ADULT, OLDER_ADULT",,"Boston Children's Hospital (Data Analysis Only), Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, 10065, United States"
NCT01482260,Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma,https://clinicaltrials.gov/study/NCT01482260,NO,Cutaneous Malignant Melanoma,PROCEDURE: Biopsy,ALL,"CHILD, ADULT, OLDER_ADULT",,"Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, NRW, 44791, Germany"
NCT03677739,Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families,https://clinicaltrials.gov/study/NCT03677739,NO,Clinical Stage 0 Cutaneous Melanoma AJCC v8|Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIC Cutaneous Melanoma AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|First Degree Relative|Pathologic Stage 0 Cutaneous Melanoma AJCC v8|Pathologic Stage I Cutaneous Melanoma AJCC v8|Pathologic Stage IA Cutaneous Melanoma AJCC v8|Pathologic Stage IB Cutaneous Melanoma AJCC v8|Pathologic Stage II Cutaneous Melanoma AJCC v8|Pathologic Stage IIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIC Cutaneous Melanoma AJCC v8|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8,OTHER: Informational Intervention|OTHER: Informational Intervention|OTHER: Survey Administration,ALL,"ADULT, OLDER_ADULT",NA,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States"
NCT02501551,"Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy",https://clinicaltrials.gov/study/NCT02501551,NO,Melanoma,DRUG: regorafenib,ALL,"ADULT, OLDER_ADULT",PHASE2,"Severance Hospital, Yonsei University Health System, Seoul, 120-752, Korea, Republic of"
